,sentence_text,e1_text,e2_text,relation_type,normalized_sentence
0,"We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ",DZNep,ABT-737,effect,also found Bcl 2 overexpressed DZNep insensitive cells cotreatment DZNep_first ABT-737_second Bcl 2 family inhibitor synergistically inhibited growth induced apoptosis DZNep insensitive MM cells.
1,"In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis. ",ABT-737,DZNep,effect,addition DZNep insensitivity might associated overexpression Bcl 2 combination ABT-737_first DZNep_second could synergistically induced apoptosis.
2,"Ephedrine enhances the antinociceptive effect of dexmedetomidine in mice.
",Ephedrine,dexmedetomidine,effect,Ephedrine_first enhances antinociceptive effect dexmedetomidine_second mice.
3,"In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. ",dexmedetomidine,ephedrine,effect,hot plate test mice co administration 15 g/kg dexmedetomidine_first 10 mg/kg ephedrine_second intraperitoneally enhanced also prolonged duration antinociception induced dexmedetomidine.
4,"At the same time, the locomotor inhibitory effect of dexmedetomidine was counteracted by ephedrine. ",dexmedetomidine,ephedrine,effect,time locomotor inhibitory effect dexmedetomidine_first counteracted ephedrine_second .
5,"We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.",dexmedetomidine,ephedrine,effect,concluded combined administration dexmedetomidine_first ephedrine_second may beneficial effects treatment pain without causing sedation limits use dexmedetomidine analgesic humans.
6,"CYP3A4 Inhibitors: Ketoconazole, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions). ",Ketoconazole,tolterodine,mechanism,CYP3A4 Inhibitors: Ketoconazole_first inhibitor drug metabolizing enzyme CYP3A4 significantly increased plasma concentrations tolterodine_second coadministered subjects poor metabolizers (see CLINICAL PHARMACOLOGY Variability Metabolism Drug Drug Interactions).
7,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",ketoconazole,DETROL LA,advise,patients receiving ketoconazole_first potent CYP3A4 inhibitors azole antifungals (eg itraconazole miconazole) macrolide antibiotics (eg erythromycin clarithromycin) cyclosporine vinblastine recommended dose DETROL LA_second 2 mg daily.
8,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",azole antifungals,DETROL LA,advise,patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals_first (eg itraconazole miconazole) macrolide antibiotics (eg erythromycin clarithromycin) cyclosporine vinblastine recommended dose DETROL LA_second 2 mg daily.
9,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",itraconazole,DETROL LA,advise,patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals (eg itraconazole_first miconazole) macrolide antibiotics (eg erythromycin clarithromycin) cyclosporine vinblastine recommended dose DETROL LA_second 2 mg daily.
10,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",miconazole,DETROL LA,advise,patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals (eg itraconazole miconazole_first ) macrolide antibiotics (eg erythromycin clarithromycin) cyclosporine vinblastine recommended dose DETROL LA_second 2 mg daily.
11,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",macrolide antibiotics,DETROL LA,advise,patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals (eg itraconazole miconazole) macrolide antibiotics_first (eg erythromycin clarithromycin) cyclosporine vinblastine recommended dose DETROL LA_second 2 mg daily.
12,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",erythromycin,DETROL LA,advise,patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals (eg itraconazole miconazole) macrolide antibiotics (eg erythromycin_first clarithromycin) cyclosporine vinblastine recommended dose DETROL LA_second 2 mg daily.
13,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",clarithromycin,DETROL LA,advise,patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals (eg itraconazole miconazole) macrolide antibiotics (eg erythromycin clarithromycin_first ) cyclosporine vinblastine recommended dose DETROL LA_second 2 mg daily.
14,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",cyclosporine,DETROL LA,advise,patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals (eg itraconazole miconazole) macrolide antibiotics (eg erythromycin clarithromycin) cyclosporine_first vinblastine recommended dose DETROL LA_second 2 mg daily.
15,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",vinblastine,DETROL LA,advise,patients receiving ketoconazole potent CYP3A4 inhibitors azole antifungals (eg itraconazole miconazole) macrolide antibiotics (eg erythromycin clarithromycin) cyclosporine vinblastine_first recommended dose DETROL LA_second 2 mg daily.
16,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",paliperidone,centrally acting drugs,advise,Given primary CNS effects paliperidone_first INVEGA used caution combination centrally acting drugs_second alcohol.
17,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",paliperidone,alcohol,advise,Given primary CNS effects paliperidone_first INVEGA used caution combination centrally acting drugs alcohol_second .
18,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",INVEGA,centrally acting drugs,advise,Given primary CNS effects paliperidone INVEGA_first used caution combination centrally acting drugs_second alcohol.
19,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",INVEGA,alcohol,advise,Given primary CNS effects paliperidone INVEGA_first used caution combination centrally acting drugs alcohol_second .
20,Paliperidone may antagonize the effect of levodopa and other dopamine agonists. ,Paliperidone,levodopa,effect,Paliperidone_first may antagonize effect levodopa_second dopamine agonists.
21,Paliperidone may antagonize the effect of levodopa and other dopamine agonists. ,Paliperidone,dopamine agonists,effect,Paliperidone_first may antagonize effect levodopa dopamine agonists_second .
22,"The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. ",oxybutynin,anticholinergic drugs,effect,concomitant use oxybutynin_first anticholinergic drugs_second agents produce dry mouth constipation somnolence (drowsiness) and/or anticholinergic like effects may increase frequency and/or severity effects.
23,"Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole, a potent CYP3A4 inhibitor. ",DITROPAN XL,ketoconazole,mechanism,Mean oxybutynin chloride plasma concentrations approximately 2 fold higher DITROPAN XL_first administered ketoconazole_second potent CYP3A4 inhibitor.
24,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",antimycotic agents,oxybutynin,mechanism,inhibitors cytochrome P450 3A4 enzyme system antimycotic agents_first (e.g. itraconazole miconazole) macrolide antibiotics (e.g. erythromycin clarithromycin) may alter oxybutynin_second mean pharmacokinetic parameters (i.e. Cmax AUC).
25,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",itraconazole,oxybutynin,mechanism,inhibitors cytochrome P450 3A4 enzyme system antimycotic agents (e.g. itraconazole_first miconazole) macrolide antibiotics (e.g. erythromycin clarithromycin) may alter oxybutynin_second mean pharmacokinetic parameters (i.e. Cmax AUC).
26,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",miconazole,oxybutynin,mechanism,inhibitors cytochrome P450 3A4 enzyme system antimycotic agents (e.g. itraconazole miconazole_first ) macrolide antibiotics (e.g. erythromycin clarithromycin) may alter oxybutynin_second mean pharmacokinetic parameters (i.e. Cmax AUC).
27,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",macrolide antibiotics,oxybutynin,mechanism,inhibitors cytochrome P450 3A4 enzyme system antimycotic agents (e.g. itraconazole miconazole) macrolide antibiotics_first (e.g. erythromycin clarithromycin) may alter oxybutynin_second mean pharmacokinetic parameters (i.e. Cmax AUC).
28,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",erythromycin,oxybutynin,mechanism,inhibitors cytochrome P450 3A4 enzyme system antimycotic agents (e.g. itraconazole miconazole) macrolide antibiotics (e.g. erythromycin_first clarithromycin) may alter oxybutynin_second mean pharmacokinetic parameters (i.e. Cmax AUC).
29,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",clarithromycin,oxybutynin,mechanism,inhibitors cytochrome P450 3A4 enzyme system antimycotic agents (e.g. itraconazole miconazole) macrolide antibiotics (e.g. erythromycin clarithromycin_first ) may alter oxybutynin_second mean pharmacokinetic parameters (i.e. Cmax AUC).
30,"Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin. ",Mitotane,warfarin,mechanism,Mitotane_first reported accelerate metabolism warfarin_second mechanism hepatic microsomal enzyme induction leading increase dosage requirements warfarin.
31,"Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants. ",Mitotane,coumarin-type anticoagulants,advise,Therefore physicians closely monitor patients change anticoagulant dosage requirements administering Mitotane_first patients coumarin-type anticoagulants_second .
32,Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing and anaphylactoid reactions. ,vancomycin,anesthetic agents,effect,Concomitant administration vancomycin_first anesthetic agents_second associated erythema histamine like flushing anaphylactoid reactions.
33,"(ii) acetyl-l-carnitine elicits a significant protective effect on DEB induced toxicity, which was potentiated by  alpha-lipoic acid.",acetyl-l-carnitine,alpha-lipoic acid,effect,(ii) acetyl-l-carnitine_first elicits significant protective effect DEB induced toxicity potentiated alpha-lipoic acid_second .
34,"However, the co   administration of SPIRIVA with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.",SPIRIVA,anticholinergic,advise,However co administration SPIRIVA_first anticholinergic_second containing drugs (e.g. ipratropium) studied therefore recommended.
35,"However, the co   administration of SPIRIVA with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.",SPIRIVA,ipratropium,advise,However co administration SPIRIVA_first anticholinergic containing drugs (e.g. ipratropium_second ) studied therefore recommended.
36,Prothrombin time or other suitable anticoagulation test should be monitored if tigecycline is administered with warfarin.   ,tigecycline,warfarin,advise,Prothrombin time suitable anticoagulation test monitored tigecycline_first administered warfarin_second .
37,Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective.  ,antibacterial drugs,contraceptives,effect,Concurrent use antibacterial drugs_first oral contraceptives_second may render oral contraceptives less effective.
38,"The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
",dasatinib,paclitaxel,effect,role p27(Kip1) dasatinib_first enhanced paclitaxel_second cytotoxicity human ovarian cancer cells.
39,HEY cells treated with dasatinib plus paclitaxel formed fewer colonies than did cells treated with either agent alone. ,dasatinib,paclitaxel,effect,HEY cells treated dasatinib_first plus paclitaxel_second formed fewer colonies cells treated either agent alone.
40,"Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",dasatinib,paclitaxel,effect,Treatment HEY xenograft bearing mice dasatinib_first plus paclitaxel_second inhibited tumor growth treatment either agent alone (average tumor volume per mouse dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3 difference = 0.53 cm3 95% confidence interval [CI] = 0.44 0.62 cm3 P = .014);
41,Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that dasatinib-mediated induction of p27(Kip1) enhanced paclitaxel-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression. ,dasatinib,paclitaxel,effect,Studies forced expression siRNA knockdown Bcl 2 Cdk1 suggest dasatinib_first mediated induction p27(Kip1) enhanced paclitaxel_second induced apoptosis negatively regulating Bcl 2 Cdk1 expression.
42,Inhibition of Src family and Abl kinases with either siRNAs or dasatinib enhances paclitaxel sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.,dasatinib,paclitaxel,effect,Inhibition Src family Abl kinases either siRNAs dasatinib_first enhances paclitaxel_second sensitivity ovarian cancer cells p27(Kip1) mediated suppression Bcl 2 Cdk1 expression.
43,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,central nervous system depressants,effect,Triprolidine_first may enhance sedative effects central nervous system depressants_second including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers.
44,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,alcohol,effect,Triprolidine_first may enhance sedative effects central nervous system depressants including alcohol_second barbiturates hypnotics narcotic analgesics sedatives tranquillisers.
45,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,barbiturates,effect,Triprolidine_first may enhance sedative effects central nervous system depressants including alcohol barbiturates_second hypnotics narcotic analgesics sedatives tranquillisers.
46,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,hypnotics,effect,Triprolidine_first may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics_second narcotic analgesics sedatives tranquillisers.
47,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,narcotic analgesics,effect,Triprolidine_first may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics_second sedatives tranquillisers.
48,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,sedatives,effect,Triprolidine_first may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives_second tranquillisers.
49,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,tranquillisers,effect,Triprolidine_first may enhance sedative effects central nervous system depressants including alcohol barbiturates hypnotics narcotic analgesics sedatives tranquillisers_second .
50,"The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ",anticholinergic drugs,triprolidine,effect,effects anticholinergic drugs_first atropine tricyclic antidepressants may enhanced concomitant administration triprolidine_second .
51,"The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ",atropine,triprolidine,effect,effects anticholinergic drugs atropine_first tricyclic antidepressants may enhanced concomitant administration triprolidine_second .
52,"The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ",tricyclic antidepressants,triprolidine,effect,effects anticholinergic drugs atropine tricyclic antidepressants_first may enhanced concomitant administration triprolidine_second .
53,"Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells.
",celecoxib,anti-cancer drugs,effect,Interaction celecoxib_first different anti-cancer drugs_second antagonistic breast cancer cells.
54,We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. ,celecoxib,doxorubicin,effect,found antagonism celecoxib four drugs breast cancer cells MCF7 following incubation schedules celecoxib_first doxorubicin_second cell lines except two combinations HCT116 cells.
55,Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.,Methergine,vasoconstrictors,advise,Caution exercised Methergine_first (methylergonovine maleate) used concurrently vasoconstrictors_second ergot alkaloids.
56,Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.,Methergine,ergot alkaloids,advise,Caution exercised Methergine_first (methylergonovine maleate) used concurrently vasoconstrictors ergot alkaloids_second .
57,Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.,methylergonovine maleate,vasoconstrictors,advise,Caution exercised Methergine (methylergonovine maleate_first ) used concurrently vasoconstrictors_second ergot alkaloids.
58,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",AGGRASTAT,heparin,effect,use AGGRASTAT_first combination heparin_second aspirin associated increase bleeding compared heparin aspirin alone (see
59,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",AGGRASTAT,aspirin,effect,use AGGRASTAT_first combination heparin aspirin_second associated increase bleeding compared heparin aspirin alone (see
60,"however, in patients with Paget's Disease prior diphosphonate use appears to reduce the anti-resorptive response to Calcitonin (salmon) nasal spray.",diphosphonate,Calcitonin (salmon),effect,however patients Paget's Disease prior diphosphonate_first use appears reduce anti resorptive response Calcitonin (salmon)_second nasal spray.
61,patients receiving lithium and Neulasta should have more frequent monitoring of neutrophil counts.,lithium,Neulasta,advise,patients receiving lithium_first Neulasta_second frequent monitoring neutrophil counts.
62,Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone. ,Sirolimus,MYCAMINE,mechanism,Sirolimus_first AUC increased 21% effect Cmax presence steady state MYCAMINE_second compared sirolimus alone.
63,"Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone. ",Nifedipine,MYCAMINE,mechanism,Nifedipine_first AUC Cmax increased 18% 42% respectively presence steady state MYCAMINE_second compared nifedipine alone.
64,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,sirolimus,MYCAMINE,advise,Patients receiving sirolimus_first nifedipine combination MYCAMINE_second monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary.
65,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,nifedipine,MYCAMINE,advise,Patients receiving sirolimus nifedipine_first combination MYCAMINE_second monitored sirolimus nifedipine toxicity sirolimus nifedipine dosage reduced necessary.
66,"Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids. ",opioids,levomepromazine,effect,Dosages concomitantly administered opioids_first reduced approximately half levomepromazine_second amplifies therapeutic actions side effects opioids.
67,"Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids. ",levomepromazine,opioids,effect,Dosages concomitantly administered opioids reduced approximately half levomepromazine_first amplifies therapeutic actions side effects opioids_second .
68,Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates. ,levomepromazine,benzodiazepines,effect,Additive sedative effects confusional states may emerge levomepromazine_first given benzodiazepines_second barbiturates.
69,Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates. ,levomepromazine,barbiturates,effect,Additive sedative effects confusional states may emerge levomepromazine_first given benzodiazepines barbiturates_second .
70,"Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",levomepromazine,anticholinergic drugs,advise,Exert particular caution combining levomepromazine_first anticholinergic drugs_second (tricyclic antidepressants antiparkinsonian agents): Particularly elderly may develop delirium high fever severe obstipation even ileus glaucoma.
71,"Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",levomepromazine,tricyclic antidepressants,advise,Exert particular caution combining levomepromazine_first anticholinergic drugs (tricyclic antidepressants_second antiparkinsonian agents): Particularly elderly may develop delirium high fever severe obstipation even ileus glaucoma.
72,"Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",levomepromazine,antiparkinsonian-agents,advise,Exert particular caution combining levomepromazine_first anticholinergic drugs (tricyclic antidepressants antiparkinsonian-agents_second ): Particularly elderly may develop delirium high fever severe obstipation even ileus glaucoma.
73,Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ,Caffeine,levomepromazine,effect,Caffeine_first and/or stimulantes ephedrine/amphetamine type may counteract specific actions levomepromazine_second .
74,Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ,ephedrine,levomepromazine,effect,Caffeine and/or stimulantes ephedrine_first /amphetamine type may counteract specific actions levomepromazine_second .
75,Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ,amphetamine,levomepromazine,effect,Caffeine and/or stimulantes ephedrine/amphetamine_first type may counteract specific actions levomepromazine_second .
76,Prior administration of succinylcholine can potentiate the neuromuscular blocking effects of nondepolarizing agents. ,succinylcholine,nondepolarizing agents,effect,Prior administration succinylcholine_first potentiate neuromuscular blocking effects nondepolarizing agents_second .
77,Evidence of spontaneous recovery from succinylcholine should be observed before the administration of MIVACRON. ,succinylcholine,MIVACRON,advise,Evidence spontaneous recovery succinylcholine_first observed administration MIVACRON_second .
78,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,antibiotics,int,drugs may enhance neuromuscular blocking action nondepolarizing agents_first MIVACRON include certain antibiotics_second (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
79,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,aminoglycosides,int,drugs may enhance neuromuscular blocking action nondepolarizing agents_first MIVACRON include certain antibiotics (e.g. aminoglycosides_second tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
80,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,tetracyclines,int,drugs may enhance neuromuscular blocking action nondepolarizing agents_first MIVACRON include certain antibiotics (e.g. aminoglycosides tetracyclines_second bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
81,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,bacitracin,int,drugs may enhance neuromuscular blocking action nondepolarizing agents_first MIVACRON include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin_second polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
82,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,polymyxins,int,drugs may enhance neuromuscular blocking action nondepolarizing agents_first MIVACRON include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins_second lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
83,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,lincomycin,int,drugs may enhance neuromuscular blocking action nondepolarizing agents_first MIVACRON include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin_second clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
84,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,clindamycin,int,drugs may enhance neuromuscular blocking action nondepolarizing agents_first MIVACRON include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin_second colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
85,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,colistin,int,drugs may enhance neuromuscular blocking action nondepolarizing agents_first MIVACRON include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin_second sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
86,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,sodium colistimethate,int,drugs may enhance neuromuscular blocking action nondepolarizing agents_first MIVACRON include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate_second ) magnesium salts lithium local anesthetics procainamide quinidine.
87,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,magnesium,int,drugs may enhance neuromuscular blocking action nondepolarizing agents_first MIVACRON include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium_second salts lithium local anesthetics procainamide quinidine.
88,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,lithium,int,drugs may enhance neuromuscular blocking action nondepolarizing agents_first MIVACRON include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium_second local anesthetics procainamide quinidine.
89,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,anesthetics,int,drugs may enhance neuromuscular blocking action nondepolarizing agents_first MIVACRON include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics_second procainamide quinidine.
90,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,procainamide,int,drugs may enhance neuromuscular blocking action nondepolarizing agents_first MIVACRON include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide_second quinidine.
91,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,quinidine,int,drugs may enhance neuromuscular blocking action nondepolarizing agents_first MIVACRON include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine_second .
92,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,antibiotics,int,drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON_first include certain antibiotics_second (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
93,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,aminoglycosides,int,drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON_first include certain antibiotics (e.g. aminoglycosides_second tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
94,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,tetracyclines,int,drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON_first include certain antibiotics (e.g. aminoglycosides tetracyclines_second bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
95,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,bacitracin,int,drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON_first include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin_second polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
96,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,polymyxins,int,drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON_first include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins_second lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
97,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,lincomycin,int,drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON_first include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin_second clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
98,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,clindamycin,int,drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON_first include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin_second colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
99,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,colistin,int,drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON_first include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin_second sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine.
100,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,sodium colistimethate,int,drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON_first include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate_second ) magnesium salts lithium local anesthetics procainamide quinidine.
101,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,magnesium,int,drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON_first include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium_second salts lithium local anesthetics procainamide quinidine.
102,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,lithium,int,drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON_first include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium_second local anesthetics procainamide quinidine.
103,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,anesthetics,int,drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON_first include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics_second procainamide quinidine.
104,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,procainamide,int,drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON_first include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide_second quinidine.
105,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,quinidine,int,drugs may enhance neuromuscular blocking action nondepolarizing agents MIVACRON_first include certain antibiotics (e.g. aminoglycosides tetracyclines bacitracin polymyxins lincomycin clindamycin colistin sodium colistimethate) magnesium salts lithium local anesthetics procainamide quinidine_second .
106,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",MIVACRON,contraceptives,effect,neuromuscular blocking effect MIVACRON_first may enhanced drugs reduce plasma cholinesterase activity (e.g. chronically administered oral contraceptives_second glucocorticoids certain monoamine oxidase inhibitors) drugs irreversibly inhibit plasma cholinesterase . Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine.
107,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",MIVACRON,glucocorticoids,effect,neuromuscular blocking effect MIVACRON_first may enhanced drugs reduce plasma cholinesterase activity (e.g. chronically administered oral contraceptives glucocorticoids_second certain monoamine oxidase inhibitors) drugs irreversibly inhibit plasma cholinesterase . Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine.
108,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",MIVACRON,monoamine oxidase inhibitors,effect,neuromuscular blocking effect MIVACRON_first may enhanced drugs reduce plasma cholinesterase activity (e.g. chronically administered oral contraceptives glucocorticoids certain monoamine oxidase inhibitors_second ) drugs irreversibly inhibit plasma cholinesterase . Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents demonstrated patients chronically administered phenytoin carbamazepine.
109,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",neuromuscular blocking agents,phenytoin,effect,neuromuscular blocking effect MIVACRON may enhanced drugs reduce plasma cholinesterase activity (e.g. chronically administered oral contraceptives glucocorticoids certain monoamine oxidase inhibitors) drugs irreversibly inhibit plasma cholinesterase . Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents_first demonstrated patients chronically administered phenytoin_second carbamazepine.
110,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",neuromuscular blocking agents,carbamazepine,effect,neuromuscular blocking effect MIVACRON may enhanced drugs reduce plasma cholinesterase activity (e.g. chronically administered oral contraceptives glucocorticoids certain monoamine oxidase inhibitors) drugs irreversibly inhibit plasma cholinesterase . Resistance neuromuscular blocking action nondepolarizing neuromuscular blocking agents_first demonstrated patients chronically administered phenytoin carbamazepine_second .
111,"While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",phenytoin,MIVACRON,effect,effects chronic phenytoin_first carbamazepine therapy action MIVACRON_second unknown slightly shorter durations neuromuscular block may anticipated infusion rate requirements may higher.
112,"While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",carbamazepine,MIVACRON,effect,effects chronic phenytoin carbamazepine_first therapy action MIVACRON_second unknown slightly shorter durations neuromuscular block may anticipated infusion rate requirements may higher.
113,The authors report the case of an infant with confirmed congenital hypothyroidism on levothyroxine who experienced a possible drug interaction with simeticone. ,levothyroxine,simeticone,int,authors report case infant confirmed congenital hypothyroidism levothyroxine_first experienced possible drug interaction simeticone_second .
114,Do not exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors. ,VESIcare,ketoconazole,advise,exceed 5 mg daily dose VESIcare_first administered therapeutic doses ketoconazole_second potent CYP3A4 inhibitors.
115,"Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects. ",minoxidil,guanethidine,effect,Interaction Guanethidine: Although minoxidil_first cause orthostatic hypotension administration patients already receiving guanethidine_second result profound orthostatic effects.
116,If at all possible guanethidine should be discontinued well before minoxidil is begun. ,guanethidine,minoxidil,advise,possible guanethidine_first discontinued well minoxidil_second begun.
117,"While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. ",ZAVESCA,Cerezyme,mechanism,co administration ZAVESCA_first appeared increase clearance Cerezyme_second 70% results conclusive small number subjects studied patients took variable doses Cerezyme.
118,Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.,Cerezyme,ZAVESCA,advise,Combination therapy Cerezyme_first (imiglucerase) ZAVESCA_second indicated.
119,Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.,imiglucerase,ZAVESCA,advise,Combination therapy Cerezyme (imiglucerase_first ) ZAVESCA_second indicated.
120,Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA. ,Aminoglutethimide,depo-subQ provera 104,mechanism,Aminoglutethimide_first administered concomitantly depo-subQ provera 104_second may significantly decrease serum concentrations MPA.
121,Thiazides may decrease arterial responsiveness to norepinephrine. ,Thiazides,norepinephrine,effect,Thiazides_first may decrease arterial responsiveness norepinephrine_second .
122,Thiazide drugs may increase the responsiveness of tubocurarine. ,Thiazide drugs,tubocurarine,effect,Thiazide drugs_first may increase responsiveness tubocurarine_second .
123,"Lithium renal clearance is reduced by thiazides, increasing the risk of lithium toxicity. ",Lithium,thiazides,mechanism,Lithium_first renal clearance reduced thiazides_second increasing risk lithium toxicity.
124,Thiazides may add to or potentiate the action of other antihypertensive drugs. ,Thiazides,antihypertensive drugs,effect,Thiazides_first may add potentiate action antihypertensive drugs_second .
125,"Diuretics: Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of ACEON    Tablets therapy. ",diuretics,ACEON,effect,Diuretics: Patients diuretics_first especially started recently may occasionally experience excessive reduction blood pressure initiation ACEON_second Tablets therapy.
126,The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with perindopril. ,diuretic,perindopril,effect,possibility hypotensive effects minimized either discontinuing diuretic_first increasing salt intake prior initiation treatment perindopril_second .
127,"If diuretics cannot be interrupted, close medical supervision should be provided with the first dose of ACEON    Tablets, for at least two hours and until blood pressure has stabilized for another hour. ",diuretics,ACEON,advise,diuretics_first cannot interrupted close medical supervision provided first dose ACEON_second Tablets least two hours blood pressure stabilized another hour.
128,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",digoxin,perindopril,mechanism,Digoxin: controlled pharmacokinetic study shown effect plasma digoxin concentrations coadministered ACEON Tablets effect digoxin_first plasma concentration perindopril_second /perindoprilat excluded.
129,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",digoxin,perindoprilat,mechanism,Digoxin: controlled pharmacokinetic study shown effect plasma digoxin concentrations coadministered ACEON Tablets effect digoxin_first plasma concentration perindopril/perindoprilat_second excluded.
130,Gentamicin: Animal data have suggested the possibility of interaction between perindopril and gentamicin. ,perindopril,gentamicin,int,Gentamicin: Animal data suggested possibility interaction perindopril_first gentamicin_second .
131,Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.,alcohol,methyprylon,effect,Concurrent use alcohol_first CNS depression producing drugs may increase CNS depressant effects methyprylon_second medications.
132,Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.,CNS depression-producing drugs,methyprylon,effect,Concurrent use alcohol CNS depression-producing drugs_first may increase CNS depressant effects methyprylon_second medications.
133,Administration of valproic acid decreases oral clearance of temozolomide by about 5%. ,valproic acid,temozolomide,mechanism,Administration valproic acid_first decreases oral clearance temozolomide_second 5%.
134,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",tolbutamide,teniposide,mechanism,study 34 different drugs tested therapeutically relevant concentrations tolbutamide_first sodium salicylate sulfamethizole displaced protein bound teniposide_second fresh human serum small significant extent.
135,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",sodium salicylate,teniposide,mechanism,study 34 different drugs tested therapeutically relevant concentrations tolbutamide sodium salicylate_first sulfamethizole displaced protein bound teniposide_second fresh human serum small significant extent.
136,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",sulfamethizole,teniposide,mechanism,study 34 different drugs tested therapeutically relevant concentrations tolbutamide sodium salicylate sulfamethizole_first displaced protein bound teniposide_second fresh human serum small significant extent.
137,An increase in intracellular levels of methotrexate was observed in vitro in the presence of teniposide.,methotrexate,teniposide,mechanism,increase intracellular levels methotrexate_first observed vitro presence teniposide_second .
138,Anticoagulants (oral): The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to methimazole.    ,anticoagulants,methimazole,effect,Anticoagulants (oral): activity oral anticoagulants_first may potentiated anti vitamin K activity attributed methimazole_second .
139,"Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). ",midazolam,cyclosporine,mechanism,Systemic apparent oral midazolam_first clearance 24% (269 73 vs. 354 102 ml/min P = 0.022) 31% (479 190 vs. 688 265 ml/min P = 0.013) respectively lower cyclosporine_second treated patients (n = 20) matched tacrolimus treated patients (n = 20).
140,Decreased seizure threshold has been reported in patients receiving CYLERT concomitantly with antiepileptic medications.,CYLERT,antiepileptic medications,effect,Decreased seizure threshold reported patients receiving CYLERT_first concomitantly antiepileptic medications_second .
141,Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.,Implanon,antiretroviral,effect,Implanon_first failure HIV positive woman antiretroviral_second therapy resulting two ectopic pregnancies.
142,We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.,antiretroviral,Implanon,effect,present interesting case HIV positive woman antiretroviral_first therapy tubal pregnancies two separate occasions Implanon_second place.
143,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,amantadine,effect,following agents may increase certain actions side effects anticholinergic drugs_first : amantadine_second antiarrhythmic agents class (e.g. quinidine) antihistamines antipsychotic agents (e.g. phenothiazines) benzodiazepines MAO inhibitors narcotic analgesics (e.g. meperidine) nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity.
144,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,antiarrhythmic agents of class I,effect,following agents may increase certain actions side effects anticholinergic drugs_first : amantadine antiarrhythmic agents class I_second (e.g. quinidine) antihistamines antipsychotic agents (e.g. phenothiazines) benzodiazepines MAO inhibitors narcotic analgesics (e.g. meperidine) nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity.
145,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,quinidine,effect,following agents may increase certain actions side effects anticholinergic drugs_first : amantadine antiarrhythmic agents class (e.g. quinidine_second ) antihistamines antipsychotic agents (e.g. phenothiazines) benzodiazepines MAO inhibitors narcotic analgesics (e.g. meperidine) nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity.
146,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,antihistamines,effect,following agents may increase certain actions side effects anticholinergic drugs_first : amantadine antiarrhythmic agents class (e.g. quinidine) antihistamines_second antipsychotic agents (e.g. phenothiazines) benzodiazepines MAO inhibitors narcotic analgesics (e.g. meperidine) nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity.
147,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,antipsychotic agents,effect,following agents may increase certain actions side effects anticholinergic drugs_first : amantadine antiarrhythmic agents class (e.g. quinidine) antihistamines antipsychotic agents_second (e.g. phenothiazines) benzodiazepines MAO inhibitors narcotic analgesics (e.g. meperidine) nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity.
148,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,phenothiazines,effect,following agents may increase certain actions side effects anticholinergic drugs_first : amantadine antiarrhythmic agents class (e.g. quinidine) antihistamines antipsychotic agents (e.g. phenothiazines_second ) benzodiazepines MAO inhibitors narcotic analgesics (e.g. meperidine) nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity.
149,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,benzodiazepines,effect,following agents may increase certain actions side effects anticholinergic drugs_first : amantadine antiarrhythmic agents class (e.g. quinidine) antihistamines antipsychotic agents (e.g. phenothiazines) benzodiazepines_second MAO inhibitors narcotic analgesics (e.g. meperidine) nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity.
150,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,MAO inhibitors,effect,following agents may increase certain actions side effects anticholinergic drugs_first : amantadine antiarrhythmic agents class (e.g. quinidine) antihistamines antipsychotic agents (e.g. phenothiazines) benzodiazepines MAO inhibitors_second narcotic analgesics (e.g. meperidine) nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity.
151,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,narcotic analgesics,effect,following agents may increase certain actions side effects anticholinergic drugs_first : amantadine antiarrhythmic agents class (e.g. quinidine) antihistamines antipsychotic agents (e.g. phenothiazines) benzodiazepines MAO inhibitors narcotic analgesics_second (e.g. meperidine) nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity.
152,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,meperidine,effect,following agents may increase certain actions side effects anticholinergic drugs_first : amantadine antiarrhythmic agents class (e.g. quinidine) antihistamines antipsychotic agents (e.g. phenothiazines) benzodiazepines MAO inhibitors narcotic analgesics (e.g. meperidine_second ) nitrates nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity.
153,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,nitrates,effect,following agents may increase certain actions side effects anticholinergic drugs_first : amantadine antiarrhythmic agents class (e.g. quinidine) antihistamines antipsychotic agents (e.g. phenothiazines) benzodiazepines MAO inhibitors narcotic analgesics (e.g. meperidine) nitrates_second nitrites sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity.
154,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,nitrites,effect,following agents may increase certain actions side effects anticholinergic drugs_first : amantadine antiarrhythmic agents class (e.g. quinidine) antihistamines antipsychotic agents (e.g. phenothiazines) benzodiazepines MAO inhibitors narcotic analgesics (e.g. meperidine) nitrates nitrites_second sympathomimetic agents tricyclic antidepressants drugs anticholinergic activity.
155,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,sympathomimetic agents,effect,following agents may increase certain actions side effects anticholinergic drugs_first : amantadine antiarrhythmic agents class (e.g. quinidine) antihistamines antipsychotic agents (e.g. phenothiazines) benzodiazepines MAO inhibitors narcotic analgesics (e.g. meperidine) nitrates nitrites sympathomimetic agents_second tricyclic antidepressants drugs anticholinergic activity.
156,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,tricyclic antidepressants,effect,following agents may increase certain actions side effects anticholinergic drugs_first : amantadine antiarrhythmic agents class (e.g. quinidine) antihistamines antipsychotic agents (e.g. phenothiazines) benzodiazepines MAO inhibitors narcotic analgesics (e.g. meperidine) nitrates nitrites sympathomimetic agents tricyclic antidepressants_second drugs anticholinergic activity.
157,Anticholinergics antagonize the effects of antiglaucoma agents. ,Anticholinergics,antiglaucoma agents,effect,Anticholinergics_first antagonize effects antiglaucoma agents_second .
158,Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. ,Anticholinergic drugs,corticosteroids,effect,Anticholinergic drugs_first presence increased intraocular pressure may hazardous taken concurrently agents corticosteroids_second .
159,"Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin; ",Anticholinergic agents,digoxin,mechanism,Anticholinergic agents_first may affect gastrointestinal absorption various drugs slowly dissolving dosage forms digoxin_second ;
160,"Anticholinergic drugs may antagonize the effects of drugs that alter gastrointestinal motility, such as metoclopramide. ",Anticholinergic drugs,metoclopramide,effect,Anticholinergic drugs_first may antagonize effects drugs alter gastrointestinal motility metoclopramide_second .
161,"Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided. ",antacids,anticholinergic agents,mechanism,antacids_first may interfere absorption anticholinergic agents_second simultaneous use drugs avoided.
162,"Ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive. ",Ropivacaine,anesthetics,advise,Ropivacaine_first used caution patients receiving local anesthetics_second agents structurally related amide type local anesthetics since toxic effects drugs additive.
163,"In vivo, the plasma clearance of ropivacaine was reduced by 70% during coadministration of fluvoxamine (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor. ",ropivacaine,fluvoxamine,mechanism,vivo plasma clearance ropivacaine_first reduced 70% coadministration fluvoxamine_second (25 mg bid 2 days) selective potent CYP1A2 inhibitor.
164,"Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. ",fluvoxamine,Ropivacaine,int,Thus strong inhibitors cytochrome P4501A2 fluvoxamine_first given concomitantly administration Ropivacaine_second interact Ropivacaine leading increased ropivacaine plasma levels.
165,"Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.",ketoconazole,ropivacaine,mechanism,Coadministration selective potent inhibitor CYP3A4 ketoconazole_first (100 mg bid 2 days ropivacaine infusion administered 1 hour ketoconazole) caused 15% reduction vivo plasma clearance ropivacaine_second .
166,It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin. ,sulfamethoxazole,warfarin,effect,reported sulfamethoxazole_first may prolong prothrombin time patients receiving anticoagulant warfarin_second .
167,Sulfamethoxazole may inhibit the hepatic metabolism of phenytoin. ,Sulfamethoxazole,phenytoin,mechanism,Sulfamethoxazole_first may inhibit hepatic metabolism phenytoin_second .
168,"At a 1.6-g dose, sulfamethoxazole produced a slight but significant increase in the half-life of phenytoin but did not produce a corresponding decrease in the metabolic clearance rate. ",sulfamethoxazole,phenytoin,mechanism,1.6 g dose sulfamethoxazole_first produced slight significant increase half life phenytoin_second produce corresponding decrease metabolic clearance rate.
169,"Sulfonamides can also displace methotrexate from plasma protein-binding sites, thus increasing free methotrexate concentrations. ",Sulfonamides,methotrexate,mechanism,Sulfonamides_first also displace methotrexate_second plasma protein binding sites thus increasing free methotrexate concentrations.
170,There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ,PURINETHOL,TABLOID,effect,usually complete cross resistance PURINETHOL_first (mercaptopurine) TABLOID_second brand Thioguanine.
171,There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ,PURINETHOL,Thioguanine,effect,usually complete cross resistance PURINETHOL_first (mercaptopurine) TABLOID brand Thioguanine_second .
172,There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ,mercaptopurine,TABLOID,effect,usually complete cross resistance PURINETHOL (mercaptopurine_first ) TABLOID_second brand Thioguanine.
173,There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ,mercaptopurine,Thioguanine,effect,usually complete cross resistance PURINETHOL (mercaptopurine_first ) TABLOID brand Thioguanine_second .
174,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",aminosalicylate derivatives,thioguanine,mechanism,vitro evidence aminosalicylate derivatives_first (e.g. olsalazine mesalazine sulphasalazine) inhibit TPMT enzyme administered caution patients receiving concurrent thioguanine_second therapy.
175,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",olsalazine,thioguanine,mechanism,vitro evidence aminosalicylate derivatives (e.g. olsalazine_first mesalazine sulphasalazine) inhibit TPMT enzyme administered caution patients receiving concurrent thioguanine_second therapy.
176,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",mesalazine,thioguanine,mechanism,vitro evidence aminosalicylate derivatives (e.g. olsalazine mesalazine_first sulphasalazine) inhibit TPMT enzyme administered caution patients receiving concurrent thioguanine_second therapy.
177,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",sulphasalazine,thioguanine,mechanism,vitro evidence aminosalicylate derivatives (e.g. olsalazine mesalazine sulphasalazine_first ) inhibit TPMT enzyme administered caution patients receiving concurrent thioguanine_second therapy.
178,"Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. ",Thalidomide,barbiturates,effect,Thalidomide_first reported enhance sedative activity barbiturates_second alcohol chlorpromazine reserpine.
179,John's Wort with hormonal contraceptive agents may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies. ,John's Wort,hormonal contraceptive agents,effect,John's Wort_first hormonal contraceptive agents_second may reduce effectiveness contraception one month discontinuation concomitant therapies.
180,"The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol. ",propoxyphene,CNS depressants,effect,CNS depressant effect propoxyphene_first additive CNS depressants_second including alcohol.
181,"The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol. ",propoxyphene,alcohol,effect,CNS depressant effect propoxyphene_first additive CNS depressants including alcohol_second .
182,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast. ",phenobarbital,montelukast,advise,reasonable employ appropriate clinical monitoring potent cytochrome P450 enzyme inducers phenobarbital_first rifampin co administered montelukast_second .
183,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast. ",rifampin,montelukast,advise,reasonable employ appropriate clinical monitoring potent cytochrome P450 enzyme inducers phenobarbital rifampin_first co administered montelukast_second .
184,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.",phenobarbital,montelukast,advise,reasonable employ appropriate clinical monitoring potent cytochrome P450 enzyme inducers phenobarbital_first rifampin co administered montelukast_second .
185,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.",rifampin,montelukast,advise,reasonable employ appropriate clinical monitoring potent cytochrome P450 enzyme inducers phenobarbital rifampin_first co administered montelukast_second .
186,"Cimetidine: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12). ",Cimetidine,pramipexole,mechanism,Cimetidine: Cimetidine_first known inhibitor renal tubular secretion organic bases via cationic transport system caused 50% increase pramipexole_second AUC 40% increase half life (N= 12).
187,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",cimetidine,pramipexole,mechanism,drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system (e.g. cimetidine_first ranitidine diltiazem triamterene verapamil quinidine quinine) decreases oral clearance pramipexole_second 20% secreted anionic transport system (e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide) likely little effect oral clearance pramipexole.
188,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",ranitidine,pramipexole,mechanism,drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system (e.g. cimetidine ranitidine_first diltiazem triamterene verapamil quinidine quinine) decreases oral clearance pramipexole_second 20% secreted anionic transport system (e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide) likely little effect oral clearance pramipexole.
189,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",diltiazem,pramipexole,mechanism,drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system (e.g. cimetidine ranitidine diltiazem_first triamterene verapamil quinidine quinine) decreases oral clearance pramipexole_second 20% secreted anionic transport system (e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide) likely little effect oral clearance pramipexole.
190,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",triamterene,pramipexole,mechanism,drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system (e.g. cimetidine ranitidine diltiazem triamterene_first verapamil quinidine quinine) decreases oral clearance pramipexole_second 20% secreted anionic transport system (e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide) likely little effect oral clearance pramipexole.
191,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",verapamil,pramipexole,mechanism,drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system (e.g. cimetidine ranitidine diltiazem triamterene verapamil_first quinidine quinine) decreases oral clearance pramipexole_second 20% secreted anionic transport system (e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide) likely little effect oral clearance pramipexole.
192,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",quinidine,pramipexole,mechanism,drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system (e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine_first quinine) decreases oral clearance pramipexole_second 20% secreted anionic transport system (e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide) likely little effect oral clearance pramipexole.
193,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",quinine,pramipexole,mechanism,drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system (e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine_first ) decreases oral clearance pramipexole_second 20% secreted anionic transport system (e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide) likely little effect oral clearance pramipexole.
194,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",cephalosporins,pramipexole,mechanism,drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system (e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine) decreases oral clearance pramipexole 20% secreted anionic transport system (e.g. cephalosporins_first penicillins indomethacin hydrochlorothiazide chlorpropamide) likely little effect oral clearance pramipexole_second .
195,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",penicillins,pramipexole,mechanism,drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system (e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine) decreases oral clearance pramipexole 20% secreted anionic transport system (e.g. cephalosporins penicillins_first indomethacin hydrochlorothiazide chlorpropamide) likely little effect oral clearance pramipexole_second .
196,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",indomethacin,pramipexole,mechanism,drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system (e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine) decreases oral clearance pramipexole 20% secreted anionic transport system (e.g. cephalosporins penicillins indomethacin_first hydrochlorothiazide chlorpropamide) likely little effect oral clearance pramipexole_second .
197,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",hydrochlorothiazide,pramipexole,mechanism,drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system (e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine) decreases oral clearance pramipexole 20% secreted anionic transport system (e.g. cephalosporins penicillins indomethacin hydrochlorothiazide_first chlorpropamide) likely little effect oral clearance pramipexole_second .
198,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",chlorpropamide,pramipexole,mechanism,drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests coadministration drugs secreted cationic transport system (e.g. cimetidine ranitidine diltiazem triamterene verapamil quinidine quinine) decreases oral clearance pramipexole 20% secreted anionic transport system (e.g. cephalosporins penicillins indomethacin hydrochlorothiazide chlorpropamide_first ) likely little effect oral clearance pramipexole_second .
199,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",dopamine antagonists,MIRAPEX,effect,Dopamine antagonists: Since pramipexole dopamine agonist possible dopamine antagonists_first neuroleptics (phenothiazines butyrophenones thioxanthenes) metoclopramide may diminish effectiveness MIRAPEX_second .
200,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",neuroleptics,MIRAPEX,effect,Dopamine antagonists: Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics_first (phenothiazines butyrophenones thioxanthenes) metoclopramide may diminish effectiveness MIRAPEX_second .
201,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",phenothiazines,MIRAPEX,effect,Dopamine antagonists: Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics (phenothiazines_first butyrophenones thioxanthenes) metoclopramide may diminish effectiveness MIRAPEX_second .
202,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",butyrophenones,MIRAPEX,effect,Dopamine antagonists: Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics (phenothiazines butyrophenones_first thioxanthenes) metoclopramide may diminish effectiveness MIRAPEX_second .
203,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",thioxanthenes,MIRAPEX,effect,Dopamine antagonists: Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics (phenothiazines butyrophenones thioxanthenes_first ) metoclopramide may diminish effectiveness MIRAPEX_second .
204,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",metoclopramide,MIRAPEX,effect,Dopamine antagonists: Since pramipexole dopamine agonist possible dopamine antagonists neuroleptics (phenothiazines butyrophenones thioxanthenes) metoclopramide_first may diminish effectiveness MIRAPEX_second .
205,"There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly. ",proton pump inhibitors,warfarin,effect,postmarketing reports increased INR prothrombin time patients receiving proton pump inhibitors_first including pantoprazole warfarin_second concomitantly.
206,"There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly. ",pantoprazole,warfarin,effect,postmarketing reports increased INR prothrombin time patients receiving proton pump inhibitors including pantoprazole_first warfarin_second concomitantly.
207,Patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and prothrombin time. ,proton pump inhibitors,warfarin,advise,Patients treated proton pump inhibitors_first warfarin_second concomitantly monitored increases INR prothrombin time.
208,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ",pantoprazole,ketoconazole,mechanism,profound long lasting inhibition gastric acid secretion pantoprazole_first may interfere absorption drugs gastric pH important determinant bioavailability (eg ketoconazole_second ampicillin esters iron salts).
209,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ",pantoprazole,ampicillin,mechanism,profound long lasting inhibition gastric acid secretion pantoprazole_first may interfere absorption drugs gastric pH important determinant bioavailability (eg ketoconazole ampicillin_second esters iron salts).
210,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ",pantoprazole,iron,mechanism,profound long lasting inhibition gastric acid secretion pantoprazole_first may interfere absorption drugs gastric pH important determinant bioavailability (eg ketoconazole ampicillin esters iron_second salts).
211,Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.,sunitinib,docetaxel,int,Synergistic interaction sunitinib_first docetaxel_second sequence dependent human non small lung cancer EGFR TKIs resistant mutation.
212,"Although single or concurrent use of sunitinib and docetaxel has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity. ",sunitinib,docetaxel,effect,Although single concurrent use sunitinib_first docetaxel_second anti proliferative effects sequential administrations drugs remarkably enhanced anti tumor activity.
213,"When cells were exposed to docetaxel followed by sunitinib, synergism was observed. ",docetaxel,sunitinib,effect,cells exposed docetaxel_first followed sunitinib_second synergism observed.
214,The molecular basis of this synergism is that the signaling pathways that were initially activated by docetaxel exposure were efficiently suppressed by the subsequent exposure to sunitinib. ,docetaxel,sunitinib,effect,molecular basis synergism signaling pathways initially activated docetaxel_first exposure efficiently suppressed subsequent exposure sunitinib_second .
215,Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.,docetaxel,sunitinib,effect,Sunitinib single agent exhibits anti proliferative effects vitro NSCLC cell lines EGFR T790M K ras mutations sequential administration docetaxel_first followed sunitinib_second superior sunitinib followed docetaxel concurrent administration.
216,Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. ,Ethanol,abacavir,mechanism,Ethanol_first decreases elimination abacavir_second causing increase overall exposure . addition methadone clinically significant effect pharmacokinetic properties abacavir.
217,"In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%). ",methadone,ZIAGEN,mechanism,study 11 HIV infected patients receiving methadone_first maintenance therapy (40 mg 90 mg daily) 600 mg ZIAGEN_second twice daily (twice currently recommended dose) oral methadone clearance increased 22% (90% CI 6% 42%).
218,"Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. ",Sulfoxone,barbiturates,effect,Sulfoxone_first may increase effects barbiturates_second tolbutamide uricosurics.
219,"Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. ",Sulfoxone,tolbutamide,effect,Sulfoxone_first may increase effects barbiturates tolbutamide_second uricosurics.
220,"Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. ",Sulfoxone,uricosurics,effect,Sulfoxone_first may increase effects barbiturates tolbutamide uricosurics_second .
221,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",Phenothiazines,CNS depressants,effect,Phenothiazines_first capable potentiating CNS depressants_second (e.g. barbiturates anesthetics opiates alcohol etc.)
222,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",Phenothiazines,barbiturates,effect,Phenothiazines_first capable potentiating CNS depressants (e.g. barbiturates_second anesthetics opiates alcohol etc.)
223,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",Phenothiazines,anesthetics,effect,Phenothiazines_first capable potentiating CNS depressants (e.g. barbiturates anesthetics_second opiates alcohol etc.)
224,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",Phenothiazines,opiates,effect,Phenothiazines_first capable potentiating CNS depressants (e.g. barbiturates anesthetics opiates_second alcohol etc.)
225,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",Phenothiazines,alcohol,effect,Phenothiazines_first capable potentiating CNS depressants (e.g. barbiturates anesthetics opiates alcohol_second etc.)
226,A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir. ,megestrol acetate,indinavir,mechanism,pharmacokinetic study demonstrated coadministration megestrol acetate_first indinavir_second results significant decrease pharmacokinetic parameters (~36% Cmax ~28% AUC) indinavir.
227,Administration of a higher dose of indinavir should be considered when coadministering with megestrol acetate. ,indinavir,megestrol acetate,advise,Administration higher dose indinavir_first considered coadministering megestrol acetate_second .
228,Streptozocin has been reported to prolong the elimination half-life of doxorubicin and may lead to severe bone marrow suppression; ,Streptozocin,doxorubicin,mechanism,Streptozocin_first reported prolong elimination half life doxorubicin_second may lead severe bone marrow suppression;
229,a reduction of the doxorubicin dosage should be considered in patients receiving ZANOSAR concurrently. ,doxorubicin,ZANOSAR,advise,reduction doxorubicin_first dosage considered patients receiving ZANOSAR_second concurrently.
230,The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity.    ,streptozocin,phenytoin,effect,concurrent use streptozocin_first phenytoin_second reported one case result reduced streptozocin cytotoxicity.
231,"Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. ",Sulfamethizole,barbiturates,effect,Sulfamethizole_first may increase effects barbiturates_second tolbutamide uricosurics.
232,"Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. ",Sulfamethizole,tolbutamide,effect,Sulfamethizole_first may increase effects barbiturates tolbutamide_second uricosurics.
233,"Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. ",Sulfamethizole,uricosurics,effect,Sulfamethizole_first may increase effects barbiturates tolbutamide uricosurics_second .
234,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",Anticoagulants,TNKase,effect,Anticoagulants_first (such heparin vitamin K antagonists) drugs alter platelet function (such acetylsalicylic acid dipyridamole GP IIb/IIIa inhibitors) may increase risk bleeding administered prior TNKase_second therapy.
235,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",heparin,TNKase,effect,Anticoagulants (such heparin_first vitamin K antagonists) drugs alter platelet function (such acetylsalicylic acid dipyridamole GP IIb/IIIa inhibitors) may increase risk bleeding administered prior TNKase_second therapy.
236,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",vitamin K antagonists,TNKase,effect,Anticoagulants (such heparin vitamin K antagonists_first ) drugs alter platelet function (such acetylsalicylic acid dipyridamole GP IIb/IIIa inhibitors) may increase risk bleeding administered prior TNKase_second therapy.
237,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",acetylsalicylic acid,TNKase,effect,Anticoagulants (such heparin vitamin K antagonists) drugs alter platelet function (such acetylsalicylic acid_first dipyridamole GP IIb/IIIa inhibitors) may increase risk bleeding administered prior TNKase_second therapy.
238,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",dipyridamole,TNKase,effect,Anticoagulants (such heparin vitamin K antagonists) drugs alter platelet function (such acetylsalicylic acid dipyridamole_first GP IIb/IIIa inhibitors) may increase risk bleeding administered prior TNKase_second therapy.
239,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ",rimantadine HCl,Cimetidine,mechanism,single 100 mg dose rimantadine HCl_first administered one hour initiation Cimetidine_second (300 mg four times day) apparent total rimantadine clearance single dose normal healthy adults reduced 18% (compared apparent total rimantadine clearance subjects absence cimetidine).
240,Coadministration with acetaminophen reduced the peak concentration and AUC values for rimantadine by approximately 11%. ,acetaminophen,rimantadine,mechanism,Coadministration acetaminophen_first reduced peak concentration AUC values rimantadine_second approximately 11%.
241,Peak plasma concentrations and AUC of rimantadine were reduced approximately 10% in the presence of aspirin.,rimantadine,aspirin,mechanism,Peak plasma concentrations AUC rimantadine_first reduced approximately 10% presence aspirin_second .
242,Trimethoprim may inhibit the hepatic metabolism of phenytoin. ,Trimethoprim,phenytoin,mechanism,Trimethoprim_first may inhibit hepatic metabolism phenytoin_second .
243,"Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%. ",Trimethoprim,phenytoin,mechanism,Trimethoprim_first given common clinical dosage increased phenytoin_second half life 51% decreased phenytoin metabolic clearance rate 30%.
244,"Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%. ",Trimethoprim,phenytoin,mechanism,Trimethoprim_first given common clinical dosage increased phenytoin half life 51% decreased phenytoin_second metabolic clearance rate 30%.
245,Pilocarpine should be administered with caution to patients taking beta adrenergic antagonists because of the possibility of conduction disturbances. ,Pilocarpine,beta adrenergic antagonists,advise,Pilocarpine_first administered caution patients taking beta adrenergic antagonists_second possibility conduction disturbances.
246,Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone; ,cyclosporin,methylprednisolone,mechanism,Mutual inhibition metabolism occurs concurrent use cyclosporin_first methylprednisolone_second ;
247,convulsions have been reported with concurrent use of methylprednisolone and cyclosporin. ,methylprednisolone,cyclosporin,effect,convulsions reported concurrent use methylprednisolone_first cyclosporin_second .
248,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",phenobarbital,methylprednisolone,mechanism,Drugs induce hepatic enzymes phenobarbital_first phenytoin rifampin may increase clearance methylprednisolone_second may require increased methylprednisolone dose achieve desired response.
249,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",phenobarbital,methylprednisolone,advise,Drugs induce hepatic enzymes phenobarbital_first phenytoin rifampin may increase clearance methylprednisolone may require increased methylprednisolone_second dose achieve desired response.
250,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",phenytoin,methylprednisolone,mechanism,Drugs induce hepatic enzymes phenobarbital phenytoin_first rifampin may increase clearance methylprednisolone_second may require increased methylprednisolone dose achieve desired response.
251,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",phenytoin,methylprednisolone,advise,Drugs induce hepatic enzymes phenobarbital phenytoin_first rifampin may increase clearance methylprednisolone may require increased methylprednisolone_second dose achieve desired response.
252,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",rifampin,methylprednisolone,mechanism,Drugs induce hepatic enzymes phenobarbital phenytoin rifampin_first may increase clearance methylprednisolone_second may require increased methylprednisolone dose achieve desired response.
253,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",rifampin,methylprednisolone,advise,Drugs induce hepatic enzymes phenobarbital phenytoin rifampin_first may increase clearance methylprednisolone may require increased methylprednisolone_second dose achieve desired response.
254,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. ,troleandomycin,methylprednisolone,mechanism,Drugs troleandomycin_first ketoconazole may inhibit metabolism methylprednisolone_second thus decrease clearance.
255,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. ,ketoconazole,methylprednisolone,mechanism,Drugs troleandomycin ketoconazole_first may inhibit metabolism methylprednisolone_second thus decrease clearance.
256,Methylprednisolone may increase the clearance of chronic high dose aspirin. ,Methylprednisolone,aspirin,mechanism,Methylprednisolone_first may increase clearance chronic high dose aspirin_second .
257,This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. ,salicylate,methylprednisolone,effect,could lead decreased salicylate serum levels increase risk salicylate_first toxicity methylprednisolone_second withdrawn.
258,Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. ,Aspirin,corticosteroids,advise,Aspirin_first used cautiously conjunction corticosteroids_second patients suffering hypoprothrombinemia.
259,There are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids. ,anticoagulant,corticosteroids,effect,reports enhanced well diminished effects anticoagulant_first given concurrently corticosteroids_second .
260,The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. ,metoclopramide,anticholinergic drugs,effect,effects metoclopramide_first gastrointestinal motility antagonized anticholinergic drugs_second narcotic analgesics.
261,The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. ,metoclopramide,narcotic analgesics,effect,effects metoclopramide_first gastrointestinal motility antagonized anticholinergic drugs narcotic analgesics_second .
262,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",metoclopramide,alcohol,effect,Additive sedative effects occur metoclopramide_first given alcohol_second sedatives hypnotics narcotics tranquilizers.
263,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",metoclopramide,sedatives,effect,Additive sedative effects occur metoclopramide_first given alcohol sedatives_second hypnotics narcotics tranquilizers.
264,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",metoclopramide,hypnotics,effect,Additive sedative effects occur metoclopramide_first given alcohol sedatives hypnotics_second narcotics tranquilizers.
265,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",metoclopramide,narcotics,effect,Additive sedative effects occur metoclopramide_first given alcohol sedatives hypnotics narcotics_second tranquilizers.
266,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",metoclopramide,tranquilizers,effect,Additive sedative effects occur metoclopramide_first given alcohol sedatives hypnotics narcotics tranquilizers_second .
267,"The finding that metoclopramide releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving monoamine oxi-dase inhibitors. ",metoclopramide,monoamine oxi-dase inhibitors,advise,finding metoclopramide_first releases catecholamines patients essential hypertension suggests used cautiously patients receiving monoamine oxi-dase inhibitors_second .
268,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",digoxin,metoclopramide,mechanism,Absorption drugs stomach may diminished (e.g. digoxin_first ) metoclopramide_second whereas rate and/or extent absorption drugs small bowel may increased (e.g. acetaminophen tetracycline levodopa ethanol cyclosporine).
269,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",metoclopramide,acetaminophen,mechanism,Absorption drugs stomach may diminished (e.g. digoxin) metoclopramide_first whereas rate and/or extent absorption drugs small bowel may increased (e.g. acetaminophen_second tetracycline levodopa ethanol cyclosporine).
270,"Because the action of metoclopramide will influence the delivery of food to the intestines and thus the rate of absorption, insulin dosage or timing of dosage may require adjustment.",metoclopramide,insulin,advise,action metoclopramide_first influence delivery food intestines thus rate absorption insulin_second dosage timing dosage may require adjustment.
271,"Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",Vasopressors,halothane,effect,Vasopressors_first particularly metaraminol may cause serious cardiac arrhythmias halothane_second anesthesia therefore used great caution all.
272,"Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",metaraminol,halothane,effect,Vasopressors particularly metaraminol_first may cause serious cardiac arrhythmias halothane_second anesthesia therefore used great caution all.
273,MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,sympathomimetic pressor amines,monoamine oxidase inhibitors,effect,MAO Inhibitors: pressor effect sympathomimetic pressor amines_first markedly potentiated patients receiving monoamine oxidase inhibitors_second (MAOI).
274,MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,sympathomimetic pressor amines,MAOI,effect,MAO Inhibitors: pressor effect sympathomimetic pressor amines_first markedly potentiated patients receiving monoamine oxidase inhibitors (MAOI_second ).
275,The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.,adrenergic agents,tricyclic antidepressants,effect,pressor response adrenergic agents_first may also potentiated tricyclic antidepressants_second .
276,"Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme. ",omeprazole,clopidogrel,mechanism,Concomitant use omeprazole_first clopidogrel_second found decrease exposure (AUC) clopidogrel's active metabolite 50% sharply increase platelet reactivity result inhibition omeprazole CYP2C19 cytochrome P450 (CYP) enzyme.
277,Pantoprazole has a much weaker effect on clopidogrel's pharmacokinetics and on platelet reactivity during concomitant use. ,Pantoprazole,clopidogrel,mechanism,Pantoprazole_first much weaker effect clopidogrel_second 's pharmacokinetics platelet reactivity concomitant use.
278,Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. ,clopidogrel,omeprazole,advise,Regulatory agencies state combination clopidogrel_first CYP2C19 inhibitors omeprazole_second esomeprazole avoided.
279,Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. ,clopidogrel,esomeprazole,advise,Regulatory agencies state combination clopidogrel_first CYP2C19 inhibitors omeprazole esomeprazole_second avoided.
280,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,tricyclic,int,Methscopolamine_first may interact antidepressants (tricyclic_second type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
281,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,MAO inhibitors,int,Methscopolamine_first may interact antidepressants (tricyclic type) MAO inhibitors_second (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
282,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,phenelzine,int,Methscopolamine_first may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine_second linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
283,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,linezolid,int,Methscopolamine_first may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid_second tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
284,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,tranylcypromine,int,Methscopolamine_first may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine_second isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
285,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,isocarboxazid,int,Methscopolamine_first may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid_second selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
286,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,selegiline,int,Methscopolamine_first may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline_second furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
287,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,furazolidone,int,Methscopolamine_first may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone_second ) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
288,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,quinidine,int,Methscopolamine_first may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine_second amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
289,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,amantadine,int,Methscopolamine_first may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine_second antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
290,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,antihistamines,int,Methscopolamine_first may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines_second (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
291,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,diphenhydramine,int,Methscopolamine_first may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine_second ) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
292,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,anticholinergics,int,Methscopolamine_first may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics_second potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
293,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,potassium chloride,int,Methscopolamine_first may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride_second supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
294,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,antacids,int,Methscopolamine_first may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids_second absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
295,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,absorbent-type anti-diarrhea medicines,int,Methscopolamine_first may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent-type anti-diarrhea medicines_second (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine).
296,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,kaolin,int,Methscopolamine_first may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin_second pectin) phenothiazines (e.g. chlorpromazine promethazine).
297,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,pectin,int,Methscopolamine_first may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin_second ) phenothiazines (e.g. chlorpromazine promethazine).
298,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,phenothiazines,int,Methscopolamine_first may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines_second (e.g. chlorpromazine promethazine).
299,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,chlorpromazine,int,Methscopolamine_first may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine_second promethazine).
300,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,promethazine,int,Methscopolamine_first may interact antidepressants (tricyclic type) MAO inhibitors (e.g. phenelzine linezolid tranylcypromine isocarboxazid selegiline furazolidone) quinidine amantadine antihistamines (e.g. diphenhydramine) anticholinergics potassium chloride supplements antacids absorbent type anti diarrhea medicines (e.g. kaolin pectin) phenothiazines (e.g. chlorpromazine promethazine_second ).
301,The preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM.,lenalidomide,CCI-779,effect,preclinical combination lenalidomide_first mTOR inhibitor CCI-779_second displayed synergy vitro represents novel combination MM.
302,"The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",ticagrelor,aspirin,effect,FDA approved ticagrelor_first (Brilinta AstraZeneca) oral antiplatelet drug use low dose aspirin_second reduce rate thrombotic cardiovascular events patients acute coronary syndrome (ACS).
303,"The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",Brilinta,aspirin,effect,FDA approved ticagrelor (Brilinta_first AstraZeneca) oral antiplatelet drug use low dose aspirin_second reduce rate thrombotic cardiovascular events patients acute coronary syndrome (ACS).
304,"Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.
",S-ketamine,ticlopidine,effect,Exposure oral S-ketamine_first unaffected itraconazole greatly increased ticlopidine_second .
305,"Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. ",Ticlopidine,ketamine,mechanism,Ticlopidine_first treatment increased mean area plasma concentration time curve extrapolated infinity (AUC(0 )) oral ketamine_second 2.4 fold whereas itraconazole treatment increase exposure ketamine.
306,The findings suggest that the dosage of S-ketamine should be reduced in patients receiving ticlopidine.,S-ketamine,ticlopidine,advise,findings suggest dosage S-ketamine_first reduced patients receiving ticlopidine_second .
307,Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.  ,antibiotics,ganglion blockers,advise,Patients receiving antibiotics_first sulfonamides generally treated ganglion blockers_second .
308,Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.  ,sulfonamides,ganglion blockers,advise,Patients receiving antibiotics sulfonamides_first generally treated ganglion blockers_second .
309,"The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.",Mecamylamine,antihypertensive drugs,effect,action Mecamylamine_first may potentiated anesthesia antihypertensive drugs_second alcohol.
310,"The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.",Mecamylamine,alcohol,effect,action Mecamylamine_first may potentiated anesthesia antihypertensive drugs alcohol_second .
311,"Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. ",metronidazole,coumarin,effect,Oral metronidazole_first reported potentiate anticoagulant effect coumarin_second warfarin resulting prolongation prothrombin time.
312,"Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. ",metronidazole,warfarin,effect,Oral metronidazole_first reported potentiate anticoagulant effect coumarin warfarin_second resulting prolongation prothrombin time.
313,Concomitant use of alcohol with phentermine hydrochloride may result in an adverse drug interaction.,alcohol,phentermine hydrochloride,int,Concomitant use alcohol_first phentermine hydrochloride_second may result adverse drug interaction.
314,Other short-acting beta adrenergic aerosol bronchodilators should not be used concomitantly with MAXAIR AUTOHALER because they may have additive effects.,short-acting beta adrenergic aerosol bronchodilators,MAXAIR AUTOHALER,advise,short-acting beta adrenergic aerosol bronchodilators_first used concomitantly MAXAIR AUTOHALER_second may additive effects.
315,A study published in 2002 found that vigabatrin causes a statistically significant increase in plasma clearance of carbamazepine. ,vigabatrin,carbamazepine,mechanism,study published 2002 found vigabatrin_first causes statistically significant increase plasma clearance carbamazepine_second .
316,"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy. ",vigabatrin,phenytoin,mechanism,1984 Drs Rimmer Richens University Wales reported administering vigabatrin_first phenytoin_second lowered serum phenytoin concentration patients treatment resistant epilepsy.
317,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",phenobarbital,corticosteroids,mechanism,Drugs induce hepatic enzymes phenobarbital_first phenytoin rifampin may increase clearance corticosteroids_second may require increases corticosteroid dose achieve desired response.
318,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",phenobarbital,corticosteroid,mechanism,Drugs induce hepatic enzymes phenobarbital_first phenytoin rifampin may increase clearance corticosteroids may require increases corticosteroid_second dose achieve desired response.
319,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",phenytoin,corticosteroids,mechanism,Drugs induce hepatic enzymes phenobarbital phenytoin_first rifampin may increase clearance corticosteroids_second may require increases corticosteroid dose achieve desired response.
320,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",phenytoin,corticosteroid,mechanism,Drugs induce hepatic enzymes phenobarbital phenytoin_first rifampin may increase clearance corticosteroids may require increases corticosteroid_second dose achieve desired response.
321,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",rifampin,corticosteroids,mechanism,Drugs induce hepatic enzymes phenobarbital phenytoin rifampin_first may increase clearance corticosteroids_second may require increases corticosteroid dose achieve desired response.
322,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",rifampin,corticosteroid,mechanism,Drugs induce hepatic enzymes phenobarbital phenytoin rifampin_first may increase clearance corticosteroids may require increases corticosteroid_second dose achieve desired response.
323,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. ,troleandomycin,corticosteroids,mechanism,Drugs troleandomycin_first ketoconazole may inhibit metabolism corticosteroids_second thus decrease clearance.
324,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. ,ketoconazole,corticosteroids,mechanism,Drugs troleandomycin ketoconazole_first may inhibit metabolism corticosteroids_second thus decrease clearance.
325,Corticosteroids may increase the clearance of chronic high dose aspirin. ,Corticosteroids,aspirin,mechanism,Corticosteroids_first may increase clearance chronic high dose aspirin_second .
326,This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. ,salicylate,corticosteroid,effect,could lead decreased salicylate serum levels increase risk salicylate_first toxicity corticosteroid_second withdrawn.
327,Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. ,Aspirin,corticosteroids,advise,Aspirin_first used cautiously conjunction corticosteroids_second patients suffering hypoprothrombinemia.
328,The effect of corticosteroids on oral anticoagulants is variable. ,corticosteroids,anticoagulants,effect,effect corticosteroids_first oral anticoagulants_second variable.
329,There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids. ,anticoagulants,corticosteroids,effect,reports enhanced well diminished effects anticoagulants_first given concurrently corticosteroids_second .
330,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Vitamin B1,Loop Diuretics,int,Interactions Vitamin B1_first (Thiamine): Loop Diuretics_second Oral Contraceptives Stavudine Tricyclic Antidepressants
331,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Vitamin B1,Contraceptives,int,Interactions Vitamin B1_first (Thiamine): Loop Diuretics Oral Contraceptives_second Stavudine Tricyclic Antidepressants
332,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Vitamin B1,Stavudine,int,Interactions Vitamin B1_first (Thiamine): Loop Diuretics Oral Contraceptives Stavudine_second Tricyclic Antidepressants
333,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Vitamin B1,Tricyclic Antidepressants,int,Interactions Vitamin B1_first (Thiamine): Loop Diuretics Oral Contraceptives Stavudine Tricyclic Antidepressants_second
334,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Thiamine,Loop Diuretics,int,Interactions Vitamin B1 (Thiamine_first ): Loop Diuretics_second Oral Contraceptives Stavudine Tricyclic Antidepressants
335,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Thiamine,Contraceptives,int,Interactions Vitamin B1 (Thiamine_first ): Loop Diuretics Oral Contraceptives_second Stavudine Tricyclic Antidepressants
336,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Thiamine,Stavudine,int,Interactions Vitamin B1 (Thiamine_first ): Loop Diuretics Oral Contraceptives Stavudine_second Tricyclic Antidepressants
337,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Thiamine,Tricyclic Antidepressants,int,Interactions Vitamin B1 (Thiamine_first ): Loop Diuretics Oral Contraceptives Stavudine Tricyclic Antidepressants_second
338,"Use with Anticholinergics: Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications. ",cholinesterase inhibitors,anticholinergic medications,int,Use Anticholinergics: mechanism action cholinesterase inhibitors_first potential interfere activity anticholinergic medications_second .
339,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",cholinesterase inhibitors,succinylcholine,effect,Use Cholinomimetics Cholinesterase Inhibitors: synergistic effect may expected cholinesterase inhibitors_first given concurrently succinylcholine_second similar neuromuscular blocking agents cholinergic agonists bethanechol.
340,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",cholinesterase inhibitors,neuromuscular blocking agents,effect,Use Cholinomimetics Cholinesterase Inhibitors: synergistic effect may expected cholinesterase inhibitors_first given concurrently succinylcholine similar neuromuscular blocking agents_second cholinergic agonists bethanechol.
341,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",cholinesterase inhibitors,cholinergic agonists,effect,Use Cholinomimetics Cholinesterase Inhibitors: synergistic effect may expected cholinesterase inhibitors_first given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists_second bethanechol.
342,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",cholinesterase inhibitors,bethanechol,effect,Use Cholinomimetics Cholinesterase Inhibitors: synergistic effect may expected cholinesterase inhibitors_first given concurrently succinylcholine similar neuromuscular blocking agents cholinergic agonists bethanechol_second .
343,"Ketoconazole: Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g. ",ketoconazole,terfenadine,effect,Ketoconazole: Spontaneous adverse reaction reports patients taking concomitant ketoconazole_first recommended doses terfenadine_second demonstrate QT interval prolongation rare serious cardiac events e.g.
344,"Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels. ",ketoconazole,terfenadine,mechanism,Pharmacokinetic data indicate ketoconazole_first markedly inhibits metabolism terfenadine_second resulting elevated plasma terfenadine levels.
345,Concomitant administration of ketoconazole and terfenadine is contraindicated. ,ketoconazole,terfenadine,advise,Concomitant administration ketoconazole_first terfenadine_second contraindicated.
346,Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,terfenadine,itraconazole,mechanism,Itraconazole: Torsades de pointes elevated parent terfenadine levels reported concomitant use terfenadine_first itraconazole_second clinical trials itraconazole foreign post marketing sources.
347,Concomitant administration of itraconazole and terfenadine is contraindicated. ,itraconazole,terfenadine,advise,Concomitant administration itraconazole_first terfenadine_second contraindicated.
348,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",azole-type antifungal agents,terfenadine,advise,Due chemical similarity azole-type antifungal agents_first (including fluconazole metronidazole miconazole) ketoconazole itraconazole concomitant use products terfenadine_second recommended pending full examination potential interactions.
349,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",fluconazole,terfenadine,advise,Due chemical similarity azole type antifungal agents (including fluconazole_first metronidazole miconazole) ketoconazole itraconazole concomitant use products terfenadine_second recommended pending full examination potential interactions.
350,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",metronidazole,terfenadine,advise,Due chemical similarity azole type antifungal agents (including fluconazole metronidazole_first miconazole) ketoconazole itraconazole concomitant use products terfenadine_second recommended pending full examination potential interactions.
351,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",miconazole,terfenadine,advise,Due chemical similarity azole type antifungal agents (including fluconazole metronidazole miconazole_first ) ketoconazole itraconazole concomitant use products terfenadine_second recommended pending full examination potential interactions.
352,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",erythromycin,terfenadine,mechanism,Macrolides: Clinical drug interaction studies indicate erythromycin_first clarithromycin exert effect terfenadine_second metabolism mechanism may similar ketoconazole lesser extent.
353,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",clarithromycin,terfenadine,mechanism,Macrolides: Clinical drug interaction studies indicate erythromycin clarithromycin_first exert effect terfenadine_second metabolism mechanism may similar ketoconazole lesser extent.
354,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,clarithromycin,advise,Concomitant administration terfenadine_first clarithromycin_second erythromycin troleandomycin contraindicated: Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended.
355,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,erythromycin,advise,Concomitant administration terfenadine_first clarithromycin erythromycin_second troleandomycin contraindicated: Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended.
356,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,troleandomycin,advise,Concomitant administration terfenadine_first clarithromycin erythromycin troleandomycin_second contraindicated: Pending full characterization potential interactions concomitant administration terfenadine macrolide antibiotics including azithromycin recommended.
357,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,macrolide antibiotics,advise,Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated: Pending full characterization potential interactions concomitant administration terfenadine_first macrolide antibiotics_second including azithromycin recommended.
358,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,azithromycin,advise,Concomitant administration terfenadine clarithromycin erythromycin troleandomycin contraindicated: Pending full characterization potential interactions concomitant administration terfenadine_first macrolide antibiotics including azithromycin_second recommended.
359,Caution is recommended when administering NEXAVAR with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. irinotecan). ,NEXAVAR,irinotecan,advise,Caution recommended administering NEXAVAR_first compounds metabolized/eliminated predominantly UGT1A1 pathway (e.g. irinotecan_second ).
360,Concomitant treatment with NEXAVAR resulted in a 21% increase in the AUC of doxorubicin. ,NEXAVAR,doxorubicin,mechanism,Concomitant treatment NEXAVAR_first resulted 21% increase AUC doxorubicin_second .
361,Caution is recommended when administering doxorubicin with NEXAVAR. ,doxorubicin,NEXAVAR,advise,Caution recommended administering doxorubicin_first NEXAVAR_second .
362,"In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2. ",mexiletine,fluvoxamine,mechanism,formal single dose interaction study (n = 6 males) clearance mexiletine_first decreased 38% following coadministration fluvoxamine_second inhibitor CYP1A2.
363,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",phenytoin,Mexitil,mechanism,phenytoin_first hepatic enzyme inducers rifampin phenobarbital taken concurrently Mexitil_second lowered Mexitil plasma levels reported.
364,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",rifampin,Mexitil,mechanism,phenytoin hepatic enzyme inducers rifampin_first phenobarbital taken concurrently Mexitil_second lowered Mexitil plasma levels reported.
365,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",phenobarbital,Mexitil,mechanism,phenytoin hepatic enzyme inducers rifampin phenobarbital_first taken concurrently Mexitil_second lowered Mexitil plasma levels reported.
366,"Concurrent administration of cimetidine and Mexitil    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels; ",cimetidine,Mexitil,mechanism,Concurrent administration cimetidine_first Mexitil_second reported increase decrease leave unchanged Mexitil plasma levels;
367,"Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",magnesium-aluminum hydroxide,digoxin,mechanism,Mexitil alter serum digoxin levels magnesium-aluminum hydroxide_first used treat gastrointestinal symptoms due Mexitil reported lower serum digoxin_second levels.
368,Concurrent use of Mexitil    and theophylline may lead to increased plasma theophylline levels. ,Mexitil,theophylline,mechanism,Concurrent use Mexitil_first theophylline_second may lead increased plasma theophylline levels.
369,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Theophylline,Mexitil,mechanism,increase observed first test point second day starting Mexitil . Theophylline_first plasma levels returned pre Mexitil values within 48 hours discontinuing Mexitil_second . Mexitil theophylline used concurrently theophylline blood levels monitored particularly Mexitil dose changed.
370,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Mexitil,theophylline,advise,increase observed first test point second day starting Mexitil . Theophylline plasma levels returned pre Mexitil values within 48 hours discontinuing Mexitil . Mexitil_first theophylline_second used concurrently theophylline blood levels monitored particularly Mexitil dose changed.
371,"Additionally, in one controlled study in five normal subjects and seven patients, the clearance of caffeine was decreased 50% following the administration of Mexitil   .",caffeine,Mexitil,mechanism,Additionally one controlled study five normal subjects seven patients clearance caffeine_first decreased 50% following administration Mexitil_second .
372,"Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.",alcohol,pentazocine,advise,Usage Alcohol: Due potential increased CNS depressants effects alcohol_first used caution patients currently receiving pentazocine_second .
373,Reduction of PTH by cinacalcet is associated with a decrease in darbepoetin requirement. ,cinacalcet,darbepoetin,effect,Reduction PTH cinacalcet_first associated decrease darbepoetin_second requirement.
374,"Thiabendazole may compete with other drugs, such as theophylline, for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels. ",Thiabendazole,theophylline,mechanism,Thiabendazole_first may compete drugs theophylline_second sites metabolism liver thus elevating serum levels compounds potentially toxic levels.
375,"Therefore, when concomitant use of thiabendazole and xanthine derivatives is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds. ",thiabendazole,xanthine derivatives,advise,Therefore concomitant use thiabendazole_first xanthine derivatives_second anticipated may necessary monitor blood levels and/or reduce dosage compounds.
376,Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.,lorazepam,pyrimethamine,effect,Mild hepatotoxicity reported patients lorazepam_first pyrimethamine_second administered concomitantly.
377,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",Warfarin,citalopram,effect,Warfarin_first users increased odds ratio gastrointestinal bleeding upon initiation citalopram_second (OR = 1.73 [95% CI 1.25 2.38]) fluoxetine (OR = 1.63 [95% CI 1.11 2.38]) paroxetine (OR = 1.64 [95% CI 1.27 2.12]) amitriptyline (OR = 1.47 [95% CI 1.02 2.11]).
378,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",Warfarin,fluoxetine,effect,Warfarin_first users increased odds ratio gastrointestinal bleeding upon initiation citalopram (OR = 1.73 [95% CI 1.25 2.38]) fluoxetine_second (OR = 1.63 [95% CI 1.11 2.38]) paroxetine (OR = 1.64 [95% CI 1.27 2.12]) amitriptyline (OR = 1.47 [95% CI 1.02 2.11]).
379,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",Warfarin,paroxetine,effect,Warfarin_first users increased odds ratio gastrointestinal bleeding upon initiation citalopram (OR = 1.73 [95% CI 1.25 2.38]) fluoxetine (OR = 1.63 [95% CI 1.11 2.38]) paroxetine_second (OR = 1.64 [95% CI 1.27 2.12]) amitriptyline (OR = 1.47 [95% CI 1.02 2.11]).
380,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",Warfarin,amitriptyline,effect,Warfarin_first users increased odds ratio gastrointestinal bleeding upon initiation citalopram (OR = 1.73 [95% CI 1.25 2.38]) fluoxetine (OR = 1.63 [95% CI 1.11 2.38]) paroxetine (OR = 1.64 [95% CI 1.27 2.12]) amitriptyline_second (OR = 1.47 [95% CI 1.02 2.11]).
381,"Also mirtazapine, which is not believed to interact with warfarin, increased the risk of GI bleeding (OR   =   1.75 [95% CI, 1.30-2.35]). ",mirtazapine,warfarin,effect,Also mirtazapine_first believed interact warfarin_second increased risk GI bleeding (OR = 1.75 [95% CI 1.30 2.35]).
382,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",Warfarin,citalopram,effect,Warfarin_first users initiated citalopram_second fluoxetine paroxetine amitriptyline mirtazapine increased risk hospitalization gastrointestinal bleeding.
383,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",Warfarin,fluoxetine,effect,Warfarin_first users initiated citalopram fluoxetine_second paroxetine amitriptyline mirtazapine increased risk hospitalization gastrointestinal bleeding.
384,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",Warfarin,paroxetine,effect,Warfarin_first users initiated citalopram fluoxetine paroxetine_second amitriptyline mirtazapine increased risk hospitalization gastrointestinal bleeding.
385,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",Warfarin,amitriptyline,effect,Warfarin_first users initiated citalopram fluoxetine paroxetine amitriptyline_second mirtazapine increased risk hospitalization gastrointestinal bleeding.
386,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",Warfarin,mirtazapine,effect,Warfarin_first users initiated citalopram fluoxetine paroxetine amitriptyline mirtazapine_second increased risk hospitalization gastrointestinal bleeding.
387,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",Posicor,terfenadine,mechanism,Posicor_first inhibits liver's ability metabolize drugs terfenadine_second astemizole cisapride cyclosporine tricyclic antidepressants.
388,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",Posicor,astemizole,mechanism,Posicor_first inhibits liver's ability metabolize drugs terfenadine astemizole_second cisapride cyclosporine tricyclic antidepressants.
389,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",Posicor,cisapride,mechanism,Posicor_first inhibits liver's ability metabolize drugs terfenadine astemizole cisapride_second cyclosporine tricyclic antidepressants.
390,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",Posicor,cyclosporine,mechanism,Posicor_first inhibits liver's ability metabolize drugs terfenadine astemizole cisapride cyclosporine_second tricyclic antidepressants.
391,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",Posicor,tricyclic antidepressants,mechanism,Posicor_first inhibits liver's ability metabolize drugs terfenadine astemizole cisapride cyclosporine tricyclic antidepressants_second .
392,"In experiment 2, the same regimen of GSLS was administered to chickens inoculated with inactivated AI vaccines, and an enhanced serum antibody response to AI vaccination was also observed. ",GSLS,inactivated AI vaccines,effect,experiment 2 regimen GSLS_first administered chickens inoculated inactivated AI vaccines_second enhanced serum antibody response AI vaccination also observed.
393,Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).,Trilostane,aminoglutethimide,int,Trilostane_first may interact aminoglutethimide_second mitotane (causing great decrease adrenal function).
394,Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).,Trilostane,mitotane,int,Trilostane_first may interact aminoglutethimide mitotane_second (causing great decrease adrenal function).
395,Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron. ,Calcium,nonheme iron,mechanism,Calcium_first known component diet may affect absorption nonheme heme nonheme iron_second .
396,Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron. ,Calcium,heme iron,mechanism,Calcium_first known component diet may affect absorption nonheme heme iron_second .
397,"However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. ",calcium,iron,mechanism,However evidence calcium_first effect iron_second absorption mainly comes studies isolate effect calcium dietary components detected single meal studies.
398,Calcium doses   1000 mg diminished nonheme iron absorption by an average of 49.6%.,Calcium,nonheme iron,mechanism,Calcium_first doses 1000 mg diminished nonheme iron_second absorption average 49.6%.
399,A calcium dose of 800 mg diminished absorption of 5 mg heme iron by 37.7%. ,calcium,heme iron,mechanism,calcium_first dose 800 mg diminished absorption 5 mg heme iron_second 37.7%.
400,"In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. ",calcium,nonheme iron,mechanism,conclusion demonstrated isolated effect calcium_first (as chloride) absorption 5 mg iron provided nonheme (as sulfate) heme (as CRBC) nonheme iron_second .
401,"In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. ",calcium,heme iron,mechanism,conclusion demonstrated isolated effect calcium_first (as chloride) absorption 5 mg iron provided nonheme (as sulfate) heme (as CRBC) heme iron_second .
402,Ritalin may decrease the hypotensive effect of guanethidine. ,Ritalin,guanethidine,effect,Ritalin_first may decrease hypotensive effect guanethidine_second .
403,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,coumarin anticoagulants,mechanism,Human pharmacologic studies shown Ritalin_first may inhibit metabolism coumarin anticoagulants_second anticonvulsants (phenobarbital diphenylhydantoin primidone) phenylbutazone tricyclic drugs (imipramine clomipramine desipramine).
404,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,anticonvulsants,mechanism,Human pharmacologic studies shown Ritalin_first may inhibit metabolism coumarin anticoagulants anticonvulsants_second (phenobarbital diphenylhydantoin primidone) phenylbutazone tricyclic drugs (imipramine clomipramine desipramine).
405,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,phenobarbital,mechanism,Human pharmacologic studies shown Ritalin_first may inhibit metabolism coumarin anticoagulants anticonvulsants (phenobarbital_second diphenylhydantoin primidone) phenylbutazone tricyclic drugs (imipramine clomipramine desipramine).
406,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,diphenylhydantoin,mechanism,Human pharmacologic studies shown Ritalin_first may inhibit metabolism coumarin anticoagulants anticonvulsants (phenobarbital diphenylhydantoin_second primidone) phenylbutazone tricyclic drugs (imipramine clomipramine desipramine).
407,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,primidone,mechanism,Human pharmacologic studies shown Ritalin_first may inhibit metabolism coumarin anticoagulants anticonvulsants (phenobarbital diphenylhydantoin primidone_second ) phenylbutazone tricyclic drugs (imipramine clomipramine desipramine).
408,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,phenylbutazone,mechanism,Human pharmacologic studies shown Ritalin_first may inhibit metabolism coumarin anticoagulants anticonvulsants (phenobarbital diphenylhydantoin primidone) phenylbutazone_second tricyclic drugs (imipramine clomipramine desipramine).
409,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,tricyclic drugs,mechanism,Human pharmacologic studies shown Ritalin_first may inhibit metabolism coumarin anticoagulants anticonvulsants (phenobarbital diphenylhydantoin primidone) phenylbutazone tricyclic drugs_second (imipramine clomipramine desipramine).
410,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,imipramine,mechanism,Human pharmacologic studies shown Ritalin_first may inhibit metabolism coumarin anticoagulants anticonvulsants (phenobarbital diphenylhydantoin primidone) phenylbutazone tricyclic drugs (imipramine_second clomipramine desipramine).
411,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,clomipramine,mechanism,Human pharmacologic studies shown Ritalin_first may inhibit metabolism coumarin anticoagulants anticonvulsants (phenobarbital diphenylhydantoin primidone) phenylbutazone tricyclic drugs (imipramine clomipramine_second desipramine).
412,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,desipramine,mechanism,Human pharmacologic studies shown Ritalin_first may inhibit metabolism coumarin anticoagulants anticonvulsants (phenobarbital diphenylhydantoin primidone) phenylbutazone tricyclic drugs (imipramine clomipramine desipramine_second ).
413,Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 ELOXATIN dosed every 3 weeks. ,5-FU,ELOXATIN,mechanism,Increases 5-FU_first plasma concentrations approximately 20% observed doses 130 mg/m2 ELOXATIN_second dosed every 3 weeks.
414,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,XENICAL,cyclosporine,mechanism,Cyclosporine: Preliminary data XENICAL cyclosporine drug interaction study indicate reduction cyclosporine plasma levels XENICAL_first coadministered cyclosporine_second .
415,Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL. ,beta-carotene,XENICAL,mechanism,Fat soluble Vitamin Supplements Analogues: pharmacokinetic interaction study showed 30% reduction beta-carotene_first supplement absorption concomitantly administered XENICAL_second .
416,XENICAL inhibited absorption of a vitamin E acetate supplement by approximately 60%. ,XENICAL,vitamin E acetate,mechanism,XENICAL_first inhibited absorption vitamin E acetate_second supplement approximately 60%.
417,"Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.",vitamin K,XENICAL,mechanism,Therefore vitamin K_first absorption may decreased XENICAL_second patients chronic stable doses warfarin prescribed XENICAL monitored closely changes coagulation parameters.
418,"Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.",warfarin,XENICAL,advise,Therefore vitamin K absorption may decreased XENICAL patients chronic stable doses warfarin_first prescribed XENICAL_second monitored closely changes coagulation parameters.
419,Terbinafine decreases the clearance of caffeine by 19%. ,Terbinafine,caffeine,mechanism,Terbinafine_first decreases clearance caffeine_second 19%.
420,Terbinafine increases the clearance of cyclosporine by 15%. ,Terbinafine,cyclosporine,mechanism,Terbinafine_first increases clearance cyclosporine_second 15%.
421,"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between LAMISIL    Tablets and these changes has not been established. ",terbinafine,warfarin,effect,spontaneous reports increase decrease prothrombin times patients concomitantly taking oral terbinafine_first warfarin_second however causal relationship LAMISIL Tablets changes established.
422,"Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. ",Terbinafine,rifampin,mechanism,Terbinafine_first clearance increased 100% rifampin_second CyP450 enzyme inducer decreased 33% cimetidine CyP450 enzyme inhibitor.
423,"Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. ",Terbinafine,cimetidine,mechanism,Terbinafine_first clearance increased 100% rifampin CyP450 enzyme inducer decreased 33% cimetidine_second CyP450 enzyme inhibitor.
424,ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ,ASPIRIN,DISALCID,effect,ASPIRIN_first SALICYLATE DRUGS ADDITIVE DISALCID_second MAY INCREASE PLASMA CONCENTRATIONS SALICYLIC ACID TOXIC LEVELS.
425,ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ,SALICYLATE DRUGS,DISALCID,effect,ASPIRIN SALICYLATE DRUGS_first ADDITIVE DISALCID_second MAY INCREASE PLASMA CONCENTRATIONS SALICYLIC ACID TOXIC LEVELS.
426,Salicylates given concomitantly with anticoagulant drugs may predispose to systemic bleeding. ,Salicylates,anticoagulant drugs,effect,Salicylates_first given concomitantly anticoagulant drugs_second may predispose systemic bleeding.
427,Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. ,Salicylates,antidiabetic drugs,effect,Salicylates_first may enhance hypoglycemic effect oral antidiabetic drugs_second sulfonylurea class.
428,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,penicillin,mechanism,Salicylate_first competes number drugs protein binding sites notably penicillin_second thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids.
429,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,thiopental,mechanism,Salicylate_first competes number drugs protein binding sites notably penicillin thiopental_second thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids.
430,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,thyroxine,mechanism,Salicylate_first competes number drugs protein binding sites notably penicillin thiopental thyroxine_second triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids.
431,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,triiodothyronine,mechanism,Salicylate_first competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine_second phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids.
432,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,phenytoin,mechanism,Salicylate_first competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin_second sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids.
433,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,sulfinpyrazone,mechanism,Salicylate_first competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone_second naproxen warfarin methotrexate possibly corticosteroids.
434,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,naproxen,mechanism,Salicylate_first competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen_second warfarin methotrexate possibly corticosteroids.
435,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,warfarin,mechanism,Salicylate_first competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin_second methotrexate possibly corticosteroids.
436,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,methotrexate,mechanism,Salicylate_first competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate_second possibly corticosteroids.
437,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,corticosteroids,mechanism,Salicylate_first competes number drugs protein binding sites notably penicillin thiopental thyroxine triiodothyronine phenytoin sulfinpyrazone naproxen warfarin methotrexate possibly corticosteroids_second .
438,"Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. ",reserpine,beta-blocking agents,effect,Catecholamine depleting drugs (e.g. reserpine_first ) may additive effect given beta-blocking agents_second .
439,Pindolol has been shown to increase serum thioridazine levels when both drugs are co-administered. ,Pindolol,thioridazine,mechanism,Pindolol_first shown increase serum thioridazine_second levels drugs co administered.
440,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",ketoconazole,mifepristone,mechanism,Although specific drug food interactions mifepristone studied basis drug metabolism CYP 3A4 possible ketoconazole_first itraconazole erythromycin grapefruit juice may inhibit metabolism (increasing serum levels mifepristone_second ).
441,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",itraconazole,mifepristone,mechanism,Although specific drug food interactions mifepristone studied basis drug metabolism CYP 3A4 possible ketoconazole itraconazole_first erythromycin grapefruit juice may inhibit metabolism (increasing serum levels mifepristone_second ).
442,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",erythromycin,mifepristone,mechanism,Although specific drug food interactions mifepristone studied basis drug metabolism CYP 3A4 possible ketoconazole itraconazole erythromycin_first grapefruit juice may inhibit metabolism (increasing serum levels mifepristone_second ).
443,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",anticonvulsants,mifepristone,mechanism,John Wort certain anticonvulsants_first (phenytoin phenobarbital carbamazepine) may induce mifepristone_second metabolism (lowering serum levels mifepristone).
444,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",phenytoin,mifepristone,mechanism,John Wort certain anticonvulsants (phenytoin_first phenobarbital carbamazepine) may induce mifepristone_second metabolism (lowering serum levels mifepristone).
445,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",phenobarbital,mifepristone,mechanism,John Wort certain anticonvulsants (phenytoin phenobarbital_first carbamazepine) may induce mifepristone_second metabolism (lowering serum levels mifepristone).
446,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",carbamazepine,mifepristone,mechanism,John Wort certain anticonvulsants (phenytoin phenobarbital carbamazepine_first ) may induce mifepristone_second metabolism (lowering serum levels mifepristone).
447,"In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ",quinpirole,amphetamine,effect,female rats neonatal quinpirole_first treatment enhanced amphetamine_second locomotor sensitization compared quinpirole free controls sensitized amphetamine.
448,Caution should be exercised when administering ZADAXIN therapy in combination with other immunomodulating drugs. ,ZADAXIN,immunomodulating drugs,advise,Caution exercised administering ZADAXIN_first therapy combination immunomodulating drugs_second .
449,Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ,DEMSER,phenothiazines,advise,Caution observed administering DEMSER_first patients receiving phenothiazines_second haloperidol extrapyramidal effects drugs expected potentiated inhibition catecholamine synthesis.
450,Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ,DEMSER,haloperidol,advise,Caution observed administering DEMSER_first patients receiving phenothiazines haloperidol_second extrapyramidal effects drugs expected potentiated inhibition catecholamine synthesis.
451,Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.,DEMSER,alcohol,effect,Concurrent use DEMSER_first alcohol_second CNS depressants increase sedative effects.
452,Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.,DEMSER,CNS depressants,effect,Concurrent use DEMSER_first alcohol CNS depressants_second increase sedative effects.
453,The metabolism of Metopirone is accelerated by phenytoin; ,Metopirone,phenytoin,mechanism,metabolism Metopirone_first accelerated phenytoin_second ;
454,Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.,Metopirone,acetaminophen,mechanism,Metopirone_first inhibits glucuronidation acetaminophen_second could possibly potentiate acetaminophen toxicity.
455,Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.,Metopirone,acetaminophen,effect,Metopirone_first inhibits glucuronidation acetaminophen could possibly potentiate acetaminophen_second toxicity.
456,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",Dopamine antagonists,Permax,advise,Dopamine antagonists_first neuroleptics (phenothiazines butyrophenones thioxanthines ) metoclopramide ordinarily administered concurrently Permax_second (a dopamine agonist);
457,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",neuroleptics,Permax,advise,Dopamine antagonists neuroleptics_first (phenothiazines butyrophenones thioxanthines ) metoclopramide ordinarily administered concurrently Permax_second (a dopamine agonist);
458,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",phenothiazines,Permax,advise,Dopamine antagonists neuroleptics (phenothiazines_first butyrophenones thioxanthines ) metoclopramide ordinarily administered concurrently Permax_second (a dopamine agonist);
459,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",butyrophenones,Permax,advise,Dopamine antagonists neuroleptics (phenothiazines butyrophenones_first thioxanthines ) metoclopramide ordinarily administered concurrently Permax_second (a dopamine agonist);
460,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",thioxanthines,Permax,advise,Dopamine antagonists neuroleptics (phenothiazines butyrophenones thioxanthines_first ) metoclopramide ordinarily administered concurrently Permax_second (a dopamine agonist);
461,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",metoclopramide,Permax,advise,Dopamine antagonists neuroleptics (phenothiazines butyrophenones thioxanthines ) metoclopramide_first ordinarily administered concurrently Permax_second (a dopamine agonist);
462,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,paricalcitol,mechanism,multiple dose drug drug interaction study demonstrated ketoconazole_first approximately doubled paricalcitol_second AUC0 . Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole.
463,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,ketoconazole,advise,multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 . Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol_first ketoconazole_second strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole.
464,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,atazanavir,advise,multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 . Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol_first ketoconazole strong P450 3A inhibitors including atazanavir_second clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole.
465,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,clarithromycin,advise,multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 . Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol_first ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin_second indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole.
466,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,indinavir,advise,multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 . Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol_first ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir_second itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole.
467,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,itraconazole,advise,multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 . Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol_first ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole_second nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole.
468,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,nefazodone,advise,multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 . Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol_first ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone_second nelfinavir ritonavir saquinavir telithromycin voriconazole.
469,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,nelfinavir,advise,multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 . Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol_first ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir_second ritonavir saquinavir telithromycin voriconazole.
470,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,ritonavir,advise,multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 . Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol_first ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir_second saquinavir telithromycin voriconazole.
471,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,saquinavir,advise,multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 . Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol_first ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir_second telithromycin voriconazole.
472,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,telithromycin,advise,multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 . Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol_first ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin_second voriconazole.
473,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,voriconazole,advise,multiple dose drug drug interaction study demonstrated ketoconazole approximately doubled paricalcitol AUC0 . Since paricalcitol partially metabolized CYP3A ketoconazole le known strong inhibitor cytochrome P450 3A enzyme care taken dosing paricalcitol_first ketoconazole strong P450 3A inhibitors including atazanavir clarithromycin indinavir itraconazole nefazodone nelfinavir ritonavir saquinavir telithromycin voriconazole_second .
474,"Dose adjustment of Zemplar Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as ketoconazole. ",Zemplar,ketoconazole,advise,Dose adjustment Zemplar_first Capsules may required iPTH serum calcium concentrations closely monitored patient initiates discontinues therapy strong CYP3A4 inhibitor ketoconazole_second .
475,"Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.",fat-soluble vitamins,cholestyramine,mechanism,Drugs impair intestinal absorption fat-soluble vitamins_first cholestyramine_second may interfere absorption Zemplar Capsules.
476,"Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.",cholestyramine,Zemplar,mechanism,Drugs impair intestinal absorption fat soluble vitamins cholestyramine_first may interfere absorption Zemplar_second Capsules.
477,The combination of minocycline and fosfomycin can be synergistic against MRSA. ,minocycline,fosfomycin,effect,combination minocycline_first fosfomycin_second synergistic MRSA.
478,"Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.",aspirin,methazolamide,advise,Caution advised patients receiving high dose aspirin_first methazolamide_second concomitantly anorexia tachypnea lethargy coma death reported concomitant use high dose aspirin carbonic anhydrase inhibitors.
479,"Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.",aspirin,carbonic anhydrase inhibitors,effect,Caution advised patients receiving high dose aspirin methazolamide concomitantly anorexia tachypnea lethargy coma death reported concomitant use high dose aspirin_first carbonic anhydrase inhibitors_second .
480,"However, interactions may be expected and FLOMAX capsules should NOT be used in combination with other alpha-adrenergic blocking agents. ",FLOMAX,alpha-adrenergic blocking agents,advise,However interactions may expected FLOMAX_first capsules used combination alpha-adrenergic blocking agents_second .
481,"Therefore, FLOMAX capsules should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg. ",FLOMAX,cimetidine,advise,Therefore FLOMAX_first capsules used caution combination cimetidine_second particularly doses higher 0.4 mg.
482,"Therefore, caution should be exercised with concomitant administration of warfarin and FLOMAX capsules.        ",warfarin,FLOMAX,advise,Therefore caution exercised concomitant administration warfarin_first FLOMAX_second capsules.
483,Limited published data indicate that GH treatment increases cytochrome P450 (CP450) mediated antipyrine clearance in man. ,GH,antipyrine,mechanism,Limited published data indicate GH_first treatment increases cytochrome P450 (CP450) mediated antipyrine_second clearance man.
484,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",GH,corticosteroids,mechanism,data suggest GH_first administration may alter clearance compounds known metabolized CP450 liver enzymes (e.g. corticosteroids_second sex steroids anticonvulsants cyclosporin).
485,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",GH,sex steroids,mechanism,data suggest GH_first administration may alter clearance compounds known metabolized CP450 liver enzymes (e.g. corticosteroids sex steroids_second anticonvulsants cyclosporin).
486,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",GH,anticonvulsants,mechanism,data suggest GH_first administration may alter clearance compounds known metabolized CP450 liver enzymes (e.g. corticosteroids sex steroids anticonvulsants_second cyclosporin).
487,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",GH,cyclosporin,mechanism,data suggest GH_first administration may alter clearance compounds known metabolized CP450 liver enzymes (e.g. corticosteroids sex steroids anticonvulsants cyclosporin_second ).
488,The CNS depressant effects of oxycodone hydrochloride may be additive with that of other CNS depressants..,oxycodone hydrochloride,CNS depressants,effect,CNS depressant effects oxycodone hydrochloride_first may additive CNS depressants_second ..
489,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",morphine,CNS depressants,effect,Use Central Nervous System Depressants: depressant effects morphine_first potentiated presence CNS depressants_second alcohol sedatives antihistaminics psychotropic drugs.
490,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",morphine,alcohol,effect,Use Central Nervous System Depressants: depressant effects morphine_first potentiated presence CNS depressants alcohol_second sedatives antihistaminics psychotropic drugs.
491,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",morphine,sedatives,effect,Use Central Nervous System Depressants: depressant effects morphine_first potentiated presence CNS depressants alcohol sedatives_second antihistaminics psychotropic drugs.
492,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",morphine,antihistaminics,effect,Use Central Nervous System Depressants: depressant effects morphine_first potentiated presence CNS depressants alcohol sedatives antihistaminics_second psychotropic drugs.
493,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",morphine,psychotropic drugs,effect,Use Central Nervous System Depressants: depressant effects morphine_first potentiated presence CNS depressants alcohol sedatives antihistaminics psychotropic drugs_second .
494,"Use of neuroleptics in conjunction with oral morphine may increase the risk of respiratory depression, hypotension and profound sedation or coma. ",neuroleptics,morphine,effect,Use neuroleptics_first conjunction oral morphine_second may increase risk respiratory depression hypotension profound sedation coma.
495,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",Agonist/antagonist analgesics,opioid agonist analgesic,advise,Interaction Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics_first (i.e. pentazocine nalbuphine butorphanol buprenorphine) administered patients received receiving course therapy proof opioid agonist analgesic_second .
496,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",pentazocine,opioid agonist analgesic,advise,Interaction Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e. pentazocine_first nalbuphine butorphanol buprenorphine) administered patients received receiving course therapy proof opioid agonist analgesic_second .
497,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",nalbuphine,opioid agonist analgesic,advise,Interaction Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e. pentazocine nalbuphine_first butorphanol buprenorphine) administered patients received receiving course therapy proof opioid agonist analgesic_second .
498,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",butorphanol,opioid agonist analgesic,advise,Interaction Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e. pentazocine nalbuphine butorphanol_first buprenorphine) administered patients received receiving course therapy proof opioid agonist analgesic_second .
499,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",buprenorphine,opioid agonist analgesic,advise,Interaction Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e. pentazocine nalbuphine butorphanol buprenorphine_first ) administered patients received receiving course therapy proof opioid agonist analgesic_second .
500,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",Myfortic,magnesium,mechanism,Antacids: Absorption single dose Myfortic_first decreased administered 12 stable renal transplant patients also taking magnesium_second aluminum containing antacids (30 mL): mean Cmax AUC(0 t) values MPA 25% 37% lower respectively Myfortic administered alone fasting conditions.
501,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",Myfortic,aluminum,mechanism,Antacids: Absorption single dose Myfortic_first decreased administered 12 stable renal transplant patients also taking magnesium aluminum_second containing antacids (30 mL): mean Cmax AUC(0 t) values MPA 25% 37% lower respectively Myfortic administered alone fasting conditions.
502,It is recommended that Myfortic and antacids not be administered simultaneously. ,Myfortic,antacids,advise,recommended Myfortic_first antacids_second administered simultaneously.
503,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",Myfortic,azathioprine,advise,Azathioprine/Mycophenolate Mofetil: Given azathioprine mycophenolate mofetil inhibit purine metabolism recommended Myfortic_first administered concomitantly azathioprine_second mycophenolate mofetil.
504,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",Myfortic,mycophenolate mofetil,advise,Azathioprine/Mycophenolate Mofetil: Given azathioprine mycophenolate mofetil inhibit purine metabolism recommended Myfortic_first administered concomitantly azathioprine mycophenolate mofetil_second .
505,"Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ",Myfortic,cholestyramine,advise,Therefore administer Myfortic_first cholestyramine_second agents may interfere enterohepatic recirculation drugs may bind bile acids example bile acid sequestrates oral activated charcoal potential reduce efficacy Myfortic.
506,"Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ",Myfortic,activated charcoal,advise,Therefore administer Myfortic_first cholestyramine agents may interfere enterohepatic recirculation drugs may bind bile acids example bile acid sequestrates oral activated charcoal_second potential reduce efficacy Myfortic.
507,"However, in a drug-drug interaction study, mean levonorgesterol AUC was decreased by 15% when coadministered with mycophenolate mofetil. ",levonorgesterol,mycophenolate mofetil,mechanism,However drug drug interaction study mean levonorgesterol_first AUC decreased 15% coadministered mycophenolate mofetil_second .
508,"Therefore, it is recommended that oral contraceptives are co- administered with Myfortic with caution and additional birth control methods be considered. ",contraceptives,Myfortic,advise,Therefore recommended oral contraceptives_first co administered Myfortic_second caution additional birth control methods considered.
509,"Live Vaccines: During treatment with Myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective. ",Myfortic,live attenuated vaccines,advise,Live Vaccines: treatment Myfortic_first use live attenuated vaccines_second avoided patients advised vaccinations may less effective.
510,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",coumarin-type anticoagulants,FELDENE,int,Although occurred vitro studies coumarin type anticoagulants interactions coumarin-type anticoagulants_first reported FELDENE_second since marketing therefore physicians closely monitor patients change dosage requirements administering FELDENE patients coumarin type anticoagulants highly protein bound drugs.
511,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",FELDENE,coumarin-type anticoagulants,advise,Although occurred vitro studies coumarin type anticoagulants interactions coumarin type anticoagulants reported FELDENE since marketing therefore physicians closely monitor patients change dosage requirements administering FELDENE_first patients coumarin-type anticoagulants_second highly protein bound drugs.
512,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",FELDENE,aspirin,mechanism,Plasma levels piroxicam depressed approximately 80% normal values FELDENE_first administered conjunction aspirin_second (3900 mg/day) concomitant administration antacids effect piroxicam plasma levels . Nonsteroidal anti inflammatory agents including FELDENE reported increase steady state plasma lithium levels.
513,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",Nonsteroidal anti-inflammatory agents,lithium,mechanism,Plasma levels piroxicam depressed approximately 80% normal values FELDENE administered conjunction aspirin (3900 mg/day) concomitant administration antacids effect piroxicam plasma levels . Nonsteroidal anti-inflammatory agents_first including FELDENE reported increase steady state plasma lithium_second levels.
514,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",FELDENE,lithium,mechanism,Plasma levels piroxicam depressed approximately 80% normal values FELDENE administered conjunction aspirin (3900 mg/day) concomitant administration antacids effect piroxicam plasma levels . Nonsteroidal anti inflammatory agents including FELDENE_first reported increase steady state plasma lithium_second levels.
515,"It is recommended that plasma lithium levels be monitored when initiating, adjusting and discontinuing FELDENE.",lithium,FELDENE,advise,recommended plasma lithium_first levels monitored initiating adjusting discontinuing FELDENE_second .
516,"Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",Vasopressors,halothane,effect,Vasopressors_first particularly metaraminol may cause serious cardiac arrhythmias halothane_second anesthesia therefore used great caution all.
517,"Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",metaraminol,halothane,effect,Vasopressors particularly metaraminol_first may cause serious cardiac arrhythmias halothane_second anesthesia therefore used great caution all.
518,MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,sympathomimetic pressor amines,monoamine oxidase inhibitors,effect,MAO Inhibitors pressor effect sympathomimetic pressor amines_first markedly potentiated patients receiving monoamine oxidase inhibitors_second (MAOI).
519,MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,sympathomimetic pressor amines,MAOI,effect,MAO Inhibitors pressor effect sympathomimetic pressor amines_first markedly potentiated patients receiving monoamine oxidase inhibitors (MAOI_second ).
520,The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.,adrenergic agents,tricyclic antidepressants,effect,pressor response adrenergic agents_first may also potentiated tricyclic antidepressants_second .
521,Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT. ,insulin,SOMAVERT,advise,Acromegalic patients diabetes mellitus treated insulin_first and/or oral hypoglycemic agents may require dose reductions therapeutic agents initiation therapy SOMAVERT_second .
522,Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT. ,hypoglycemic,SOMAVERT,advise,Acromegalic patients diabetes mellitus treated insulin and/or oral hypoglycemic_first agents may require dose reductions therapeutic agents initiation therapy SOMAVERT_second .
523,"In clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids. ",opioids,pegvisomant,mechanism,clinical studies patients opioids_first often needed higher serum pegvisomant_second concentrations achieve appropriate IGF suppression compared patients receiving opioids.
524,"Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days. ",digoxin,sitagliptin,mechanism,Digoxin: slight increase area curve (AUC 11%) mean peak drug concentration (Cmax 18%) digoxin_first co administration 100 mg sitagliptin_second 10 days.
525,Limited evidence suggests that ascorbic acid may influence the intensity and duration of action of bishydroxycoumarin.,ascorbic acid,bishydroxycoumarin,mechanism,Limited evidence suggests ascorbic acid_first may influence intensity duration action bishydroxycoumarin_second .
526,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Vindesine,Phenytoin,int,Vindesine_first interact drugs following categories: Blood dyscrasia: cause unpredictable myelotoxicity Bone marrow depressants: cause predictable dose related myelotoxicity Radiation therapy: may cause marrow depression Neurotoxic medications: cause neurologic toxicity Phenytoin_second : increase seizure activity Live virus vaccines: may potentiate replication vaccine virus may increase side effects vaccination decrease patient's response vaccine Mitomycin C: may cause shortness breath bronchospasm Killed virus vaccines: may decrease patient's response vaccine
527,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Vindesine,Live virus vaccines,int,Vindesine_first interact drugs following categories: Blood dyscrasia: cause unpredictable myelotoxicity Bone marrow depressants: cause predictable dose related myelotoxicity Radiation therapy: may cause marrow depression Neurotoxic medications: cause neurologic toxicity Phenytoin: increase seizure activity Live virus vaccines_second : may potentiate replication vaccine virus may increase side effects vaccination decrease patient's response vaccine Mitomycin C: may cause shortness breath bronchospasm Killed virus vaccines: may decrease patient's response vaccine
528,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Vindesine,Mitomycin-C,int,Vindesine_first interact drugs following categories: Blood dyscrasia: cause unpredictable myelotoxicity Bone marrow depressants: cause predictable dose related myelotoxicity Radiation therapy: may cause marrow depression Neurotoxic medications: cause neurologic toxicity Phenytoin: increase seizure activity Live virus vaccines: may potentiate replication vaccine virus may increase side effects vaccination decrease patient's response vaccine Mitomycin-C_second : may cause shortness breath bronchospasm Killed virus vaccines: may decrease patient's response vaccine
529,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Vindesine,Killed virus vaccines,int,Vindesine_first interact drugs following categories: Blood dyscrasia: cause unpredictable myelotoxicity Bone marrow depressants: cause predictable dose related myelotoxicity Radiation therapy: may cause marrow depression Neurotoxic medications: cause neurologic toxicity Phenytoin: increase seizure activity Live virus vaccines: may potentiate replication vaccine virus may increase side effects vaccination decrease patient's response vaccine Mitomycin C: may cause shortness breath bronchospasm Killed virus vaccines_second : may decrease patient's response vaccine
530,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",potassium-sparing diuretics,ACE inhibitors,effect,Use potassium-sparing diuretics_first (spironolactone triamterene amiloride) potassium supplements concomitantly ACE inhibitors_second increase risk hyperkalemia.
531,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",spironolactone,ACE inhibitors,effect,Use potassium sparing diuretics (spironolactone_first triamterene amiloride) potassium supplements concomitantly ACE inhibitors_second increase risk hyperkalemia.
532,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",triamterene,ACE inhibitors,effect,Use potassium sparing diuretics (spironolactone triamterene_first amiloride) potassium supplements concomitantly ACE inhibitors_second increase risk hyperkalemia.
533,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",amiloride,ACE inhibitors,effect,Use potassium sparing diuretics (spironolactone triamterene amiloride_first ) potassium supplements concomitantly ACE inhibitors_second increase risk hyperkalemia.
534,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",potassium,ACE inhibitors,effect,Use potassium sparing diuretics (spironolactone triamterene amiloride) potassium_first supplements concomitantly ACE inhibitors_second increase risk hyperkalemia.
535,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,ACE inhibitors,lithium,effect,Lithium: Increased serum lithium levels symptoms lithium toxicity reported patients receiving ACE inhibitors_first therapy lithium_second .
536,"If a diuretic is also used, the risk of lithium toxicity may be increased. ",diuretic,lithium,effect,diuretic_first also used risk lithium_second toxicity may increased.
537,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,aspirin,int,Melatonin_first may interact following drugs: aspirin_second NSAIDs (may lower melatonin levels) fluvoxamine (bioavailability oral melatonin increased coadministration) beta blockers (may decrease melatonin levels) fluoxetine (reports psychotic episodes coadministered) progestin (coadministration melatonin progestin inhibit ovarian function women) benzodiazepenes sedating drugs (may result additive sedation increased incidence adverse effects) corticosteroids (coadministration melatonin corticosteroids may interfere efficacy corticosteroids).
538,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,NSAIDs,int,Melatonin_first may interact following drugs: aspirin NSAIDs_second (may lower melatonin levels) fluvoxamine (bioavailability oral melatonin increased coadministration) beta blockers (may decrease melatonin levels) fluoxetine (reports psychotic episodes coadministered) progestin (coadministration melatonin progestin inhibit ovarian function women) benzodiazepenes sedating drugs (may result additive sedation increased incidence adverse effects) corticosteroids (coadministration melatonin corticosteroids may interfere efficacy corticosteroids).
539,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,fluvoxamine,int,Melatonin_first may interact following drugs: aspirin NSAIDs (may lower melatonin levels) fluvoxamine_second (bioavailability oral melatonin increased coadministration) beta blockers (may decrease melatonin levels) fluoxetine (reports psychotic episodes coadministered) progestin (coadministration melatonin progestin inhibit ovarian function women) benzodiazepenes sedating drugs (may result additive sedation increased incidence adverse effects) corticosteroids (coadministration melatonin corticosteroids may interfere efficacy corticosteroids).
540,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,beta blockers,int,Melatonin_first may interact following drugs: aspirin NSAIDs (may lower melatonin levels) fluvoxamine (bioavailability oral melatonin increased coadministration) beta blockers_second (may decrease melatonin levels) fluoxetine (reports psychotic episodes coadministered) progestin (coadministration melatonin progestin inhibit ovarian function women) benzodiazepenes sedating drugs (may result additive sedation increased incidence adverse effects) corticosteroids (coadministration melatonin corticosteroids may interfere efficacy corticosteroids).
541,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,fluoxetine,int,Melatonin_first may interact following drugs: aspirin NSAIDs (may lower melatonin levels) fluvoxamine (bioavailability oral melatonin increased coadministration) beta blockers (may decrease melatonin levels) fluoxetine_second (reports psychotic episodes coadministered) progestin (coadministration melatonin progestin inhibit ovarian function women) benzodiazepenes sedating drugs (may result additive sedation increased incidence adverse effects) corticosteroids (coadministration melatonin corticosteroids may interfere efficacy corticosteroids).
542,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,progestin,int,Melatonin_first may interact following drugs: aspirin NSAIDs (may lower melatonin levels) fluvoxamine (bioavailability oral melatonin increased coadministration) beta blockers (may decrease melatonin levels) fluoxetine (reports psychotic episodes coadministered) progestin_second (coadministration melatonin progestin inhibit ovarian function women) benzodiazepenes sedating drugs (may result additive sedation increased incidence adverse effects) corticosteroids (coadministration melatonin corticosteroids may interfere efficacy corticosteroids).
543,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,benzodiazepenes,int,Melatonin_first may interact following drugs: aspirin NSAIDs (may lower melatonin levels) fluvoxamine (bioavailability oral melatonin increased coadministration) beta blockers (may decrease melatonin levels) fluoxetine (reports psychotic episodes coadministered) progestin (coadministration melatonin progestin inhibit ovarian function women) benzodiazepenes_second sedating drugs (may result additive sedation increased incidence adverse effects) corticosteroids (coadministration melatonin corticosteroids may interfere efficacy corticosteroids).
544,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,corticosteroids,int,Melatonin_first may interact following drugs: aspirin NSAIDs (may lower melatonin levels) fluvoxamine (bioavailability oral melatonin increased coadministration) beta blockers (may decrease melatonin levels) fluoxetine (reports psychotic episodes coadministered) progestin (coadministration melatonin progestin inhibit ovarian function women) benzodiazepenes sedating drugs (may result additive sedation increased incidence adverse effects) corticosteroids_second (coadministration melatonin corticosteroids may interfere efficacy corticosteroids).
545,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,progestin,effect,Melatonin may interact following drugs: aspirin NSAIDs (may lower melatonin levels) fluvoxamine (bioavailability oral melatonin increased coadministration) beta blockers (may decrease melatonin levels) fluoxetine (reports psychotic episodes coadministered) progestin (coadministration melatonin_first progestin_second inhibit ovarian function women) benzodiazepenes sedating drugs (may result additive sedation increased incidence adverse effects) corticosteroids (coadministration melatonin corticosteroids may interfere efficacy corticosteroids).
546,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,corticosteroids,effect,Melatonin may interact following drugs: aspirin NSAIDs (may lower melatonin levels) fluvoxamine (bioavailability oral melatonin increased coadministration) beta blockers (may decrease melatonin levels) fluoxetine (reports psychotic episodes coadministered) progestin (coadministration melatonin progestin inhibit ovarian function women) benzodiazepenes sedating drugs (may result additive sedation increased incidence adverse effects) corticosteroids (coadministration melatonin_first corticosteroids_second may interfere efficacy corticosteroids).
547,Alcohol: Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects. ,alcohol,mirtazapine,mechanism,Alcohol: Concomitant administration alcohol_first (equivalent 60 g) minimal effect plasma levels mirtazapine_second (15 mg) 6 healthy male subjects.
548,"However, the impairment of cognitive and motor skills produced by REMERON    were shown to be additive with those produced by alcohol. ",REMERON,alcohol,effect,However impairment cognitive motor skills produced REMERON_first shown additive produced alcohol_second .
549,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",alcohol,REMERON SolTab,advise,Accordingly patients advised avoid alcohol_first taking REMERON SolTab_second . Diazepam: Concomitant administration diazepam (15 mg) minimal effect plasma levels mirtazapine (15 mg) 12 healthy subjects.
550,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",diazepam,mirtazapine,mechanism,Accordingly patients advised avoid alcohol taking REMERON SolTab. Diazepam: Concomitant administration diazepam_first (15 mg) minimal effect plasma levels mirtazapine_second (15 mg) 12 healthy subjects.
551,"However, the impairment of motor skills produced by REMERON has been shown to be additive with those caused by diazepam. ",REMERON,diazepam,effect,However impairment motor skills produced REMERON_first shown additive caused diazepam_second .
552,"Accordingly, patients should be advised to avoid diazepam and other similar drugs while taking REMERON SolTab.",diazepam,REMERON SolTab,advise,Accordingly patients advised avoid diazepam_first similar drugs taking REMERON SolTab_second .
553,Drug Interactions: Women on oral contraceptives have shown a significant increase in plasma vitamin A levels.,contraceptives,vitamin A,mechanism,Drug Interactions: Women oral contraceptives_first shown significant increase plasma vitamin A_second levels.
554,"Concomitant administration of CHEMET with other chelation therapy, such as CaNa 2 EDTA is not recommended. ",CHEMET,CaNa 2 EDTA,advise,Concomitant administration CHEMET_first chelation therapy CaNa 2 EDTA_second recommended.
555,AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. ,AAV2,heparinase III,effect,AAV2_first mediated retinal transduction improved co injection heparinase III_second chondroitin ABC lyase.
556,AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. ,AAV2,chondroitin ABC lyase,effect,AAV2_first mediated retinal transduction improved co injection heparinase III chondroitin ABC lyase_second .
557,"When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. ",methyldopa,antihypertensive drugs,effect,methyldopa_first used antihypertensive drugs_second potentiation antihypertensive effect may occur.
558,Patients may require reduced doses of anesthetics when on methyldopa. ,anesthetics,methyldopa,advise,Patients may require reduced doses anesthetics_first methyldopa_second .
559,When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. ,methyldopa,lithium,advise,methyldopa_first lithium_second given concomitantly patient carefully monitored symptoms lithium toxicity.
560,Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate. ,methyldopa,ferrous sulfate,mechanism,Several studies demonstrate decrease bioavailability methyldopa_first ingested ferrous sulfate_second ferrous gluconate.
561,Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate. ,methyldopa,ferrous gluconate,mechanism,Several studies demonstrate decrease bioavailability methyldopa_first ingested ferrous sulfate ferrous gluconate_second .
562,Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. ,methyldopa,ferrous sulfate,advise,Coadministration methyldopa_first ferrous sulfate_second ferrous gluconate recommended.
563,Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. ,methyldopa,ferrous gluconate,advise,Coadministration methyldopa_first ferrous sulfate ferrous gluconate_second recommended.
564,norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. ,norepinephrine,sodium bicarbonate,int,norepinephrine_first dobutamine incompatible sodium bicarbonate_second solution.
565,norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. ,dobutamine,sodium bicarbonate,int,norepinephrine dobutamine_first incompatible sodium bicarbonate_second solution.
566,"CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. ",CRM197,doxorubicin,effect,CRM197 induced apoptosis furthermore combination CRM197_first plus doxorubicin_second enhanced cytotoxicity cell line.
567,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",SKELID,calcium,mechanism,bioavailability SKELID_first decreased 80% calcium_second calcium SKELID administered time 60% aluminum magnesium containing antacids administered 1 hour SKELID.
568,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",aluminum,SKELID,mechanism,bioavailability SKELID decreased 80% calcium calcium SKELID administered time 60% aluminum_first magnesium containing antacids administered 1 hour SKELID_second .
569,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",magnesium,SKELID,mechanism,bioavailability SKELID decreased 80% calcium calcium SKELID administered time 60% aluminum magnesium_first containing antacids administered 1 hour SKELID_second .
570,Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID. ,Aspirin,SKELID,mechanism,Aspirin_first may decrease bioavailability SKELID_second 50% taken 2 hours SKELID.
571,The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac. ,SKELID,indomethacin,mechanism,bioavailability SKELID_first increased 2 4 fold indomethacin_second significantly altered coadministration diclofenac.
572,"Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.",Tetracycline,penicillin,effect,Tetracycline_first bacteriostatic antibiotic may antagonize bactericidal effect penicillin_second concurrent use drugs avoided.
573,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",DIPRIVAN,narcotics,effect,induction dose requirements DIPRIVAN_first Injectable Emulsion may reduced patients intramuscular intravenous premedication particularly narcotics_second (eg morphine meperidine fentanyl etc.)
574,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",DIPRIVAN,morphine,effect,induction dose requirements DIPRIVAN_first Injectable Emulsion may reduced patients intramuscular intravenous premedication particularly narcotics (eg morphine_second meperidine fentanyl etc.)
575,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",DIPRIVAN,meperidine,effect,induction dose requirements DIPRIVAN_first Injectable Emulsion may reduced patients intramuscular intravenous premedication particularly narcotics (eg morphine meperidine_second fentanyl etc.)
576,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",DIPRIVAN,fentanyl,effect,induction dose requirements DIPRIVAN_first Injectable Emulsion may reduced patients intramuscular intravenous premedication particularly narcotics (eg morphine meperidine fentanyl_second etc.)
577,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ",DIPRIVAN,analgesic agents,advise,maintenance anesthesia sedation rate DIPRIVAN_first Injectable Emulsion administration adjusted according desired level anesthesia sedation may reduced presence supplemental analgesic agents_second (eg nitrous oxide opioids).
578,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ",DIPRIVAN,nitrous oxide,advise,maintenance anesthesia sedation rate DIPRIVAN_first Injectable Emulsion administration adjusted according desired level anesthesia sedation may reduced presence supplemental analgesic agents (eg nitrous oxide_second opioids).
579,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ",DIPRIVAN,opioids,advise,maintenance anesthesia sedation rate DIPRIVAN_first Injectable Emulsion administration adjusted according desired level anesthesia sedation may reduced presence supplemental analgesic agents (eg nitrous oxide opioids_second ).
580,"Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.",ketamine,propofol,effect,Based experience suggest low dose ketamine_first added propofol_second may associated prevention EA children history EA propofol TIVA.
581,"However, increased prothrombin time and bleeding have been reported in patients on concomitant TOLECTIN and warfarin therapy. ",TOLECTIN,warfarin,effect,However increased prothrombin time bleeding reported patients concomitant TOLECTIN_first warfarin_second therapy.
582,"Therefore, caution should be exercised when administering TOLECTIN to patients on anticoagulants. ",TOLECTIN,anticoagulants,advise,Therefore caution exercised administering TOLECTIN_first patients anticoagulants_second .
583,Caution should be used if TOLECTIN is administered concomitantly with methotrexate. ,TOLECTIN,methotrexate,advise,Caution used TOLECTIN_first administered concomitantly methotrexate_second .
584,"TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. ",TOLECTIN,methotrexate,mechanism,TOLECTIN_first nonsteroidal anti inflammatory drugs reported reduce tubular secretion methotrexate_second animal model possibly enhancing toxicity methotrexate.
585,"TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. ",nonsteroidal anti-inflammatory drugs,methotrexate,mechanism,TOLECTIN nonsteroidal anti-inflammatory drugs_first reported reduce tubular secretion methotrexate_second animal model possibly enhancing toxicity methotrexate.
586,Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. ,Thiazide diuretics,phenothiazines,effect,Thiazide diuretics_first may accentuate orthostatic hypotension may occur phenothiazines_second .
587,Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly. ,guanethidine,phenothiazines,effect,Antihypertensive effects guanethidine_first related compounds may counteracted phenothiazines_second used concomitantly.
588,Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.,propranolol,phenothiazines,mechanism,Concomitant administration propranolol_first phenothiazines_second results increased plasma levels drugs.
589,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,dornase alfa,effect,clinical studies TOBI patients taking TOBI_first concomitantly dornase alfa_second (PULMOZYME Genentech) (beta) agonists inhaled corticosteroids anti pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole.
590,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,PULMOZYME,effect,clinical studies TOBI patients taking TOBI_first concomitantly dornase alfa (PULMOZYME_second Genentech) (beta) agonists inhaled corticosteroids anti pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole.
591,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,(beta)-agonists,effect,clinical studies TOBI patients taking TOBI_first concomitantly dornase alfa (PULMOZYME Genentech) (beta)-agonists_second inhaled corticosteroids anti pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole.
592,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,corticosteroids,effect,clinical studies TOBI patients taking TOBI_first concomitantly dornase alfa (PULMOZYME Genentech) (beta) agonists inhaled corticosteroids_second anti pseudomonal antibiotics parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole.
593,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,anti-pseudomonal antibiotics,effect,clinical studies TOBI patients taking TOBI_first concomitantly dornase alfa (PULMOZYME Genentech) (beta) agonists inhaled corticosteroids anti-pseudomonal antibiotics_second parenteral aminoglycosides demonstrated adverse experience profiles similar study population whole.
594,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,aminoglycosides,effect,clinical studies TOBI patients taking TOBI_first concomitantly dornase alfa (PULMOZYME Genentech) (beta) agonists inhaled corticosteroids anti pseudomonal antibiotics parenteral aminoglycosides_second demonstrated adverse experience profiles similar study population whole.
595,Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. ,diuretics,aminoglycoside,effect,diuretics_first enhance aminoglycoside_second toxicity altering antibiotic concentrations serum tissue.
596,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",TOBI,ethacrynic acid,advise,TOBI_first administered concomitantly ethacrynic acid_second furosemide urea mannitol.
597,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",TOBI,furosemide,advise,TOBI_first administered concomitantly ethacrynic acid furosemide_second urea mannitol.
598,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",TOBI,urea,advise,TOBI_first administered concomitantly ethacrynic acid furosemide urea_second mannitol.
599,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",TOBI,mannitol,advise,TOBI_first administered concomitantly ethacrynic acid furosemide urea mannitol_second .
600,An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. ,gemfibrozil,rosiglitazone,mechanism,inhibitor CYP2C8 (such gemfibrozil_first ) may increase AUC rosiglitazone_second inducer CYP2C8 (such rifampin) may decrease AUC rosiglitazone.
601,An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. ,rifampin,rosiglitazone,mechanism,inhibitor CYP2C8 (such gemfibrozil) may increase AUC rosiglitazone inducer CYP2C8 (such rifampin_first ) may decrease AUC rosiglitazone_second .
602,Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. ,Cholestyramine,raloxifene,mechanism,Cholestyramine: Cholestyramine_first causes 60% reduction absorption enterohepatic cycling raloxifene_second coadministered EVISTA.
603,Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. ,Cholestyramine,EVISTA,advise,Cholestyramine: Cholestyramine_first causes 60% reduction absorption enterohepatic cycling raloxifene coadministered EVISTA_second .
604,"If EVISTA is given concurrently with warfarin, prothrombin time should be monitored. ",EVISTA,warfarin,advise,EVISTA_first given concurrently warfarin_second prothrombin time monitored.
605,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,clofibrate,advise,Caution used EVISTA_first coadministered highly protein bound drugs clofibrate_second indomethacin naproxen ibuprofen diazepam diazoxide.
606,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,indomethacin,advise,Caution used EVISTA_first coadministered highly protein bound drugs clofibrate indomethacin_second naproxen ibuprofen diazepam diazoxide.
607,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,naproxen,advise,Caution used EVISTA_first coadministered highly protein bound drugs clofibrate indomethacin naproxen_second ibuprofen diazepam diazoxide.
608,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,ibuprofen,advise,Caution used EVISTA_first coadministered highly protein bound drugs clofibrate indomethacin naproxen ibuprofen_second diazepam diazoxide.
609,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,diazepam,advise,Caution used EVISTA_first coadministered highly protein bound drugs clofibrate indomethacin naproxen ibuprofen diazepam_second diazoxide.
610,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,diazoxide,advise,Caution used EVISTA_first coadministered highly protein bound drugs clofibrate indomethacin naproxen ibuprofen diazepam diazoxide_second .
611,Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent    (metaproterenol sulfate USP) because they may have additive effects. ,beta adrenergic aerosol bronchodilators,Alupent,advise,beta adrenergic aerosol bronchodilators_first used concomitantly Alupent_second (metaproterenol sulfate USP) may additive effects.
612,Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent    (metaproterenol sulfate USP) because they may have additive effects. ,beta adrenergic aerosol bronchodilators,metaproterenol sulfate,advise,beta adrenergic aerosol bronchodilators_first used concomitantly Alupent (metaproterenol sulfate_second USP) may additive effects.
613,"Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.",Beta adrenergic agonists,monoamine oxidase inhibitors,advise,Beta adrenergic agonists_first administered caution patients treated monoamine oxidase inhibitors_second tricyclic antidepressants since action beta adrenergic agonists vascular system may potentiated.
614,"Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.",Beta adrenergic agonists,tricyclic antidepressants,advise,Beta adrenergic agonists_first administered caution patients treated monoamine oxidase inhibitors tricyclic antidepressants_second since action beta adrenergic agonists vascular system may potentiated.
615,"If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed. ",ZEMURON,succinylcholine,advise,ZEMURON_first administered following administration succinylcholine_second given recovery succinylcholine observed.
616,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",phenytoin,ondansetron,mechanism,Phenytoin Carbamazepine Rifampicin: patients treated potent inducers CYP3A4 (i.e. phenytoin_first carbamazepine rifampicin) clearance ondansetron_second significantly increased ondansetron blood concentrations decreased.
617,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",phenytoin,ondansetron,mechanism,Phenytoin Carbamazepine Rifampicin: patients treated potent inducers CYP3A4 (i.e. phenytoin_first carbamazepine rifampicin) clearance ondansetron significantly increased ondansetron_second blood concentrations decreased.
618,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",carbamazepine,ondansetron,mechanism,Phenytoin Carbamazepine Rifampicin: patients treated potent inducers CYP3A4 (i.e. phenytoin carbamazepine_first rifampicin) clearance ondansetron_second significantly increased ondansetron blood concentrations decreased.
619,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",carbamazepine,ondansetron,mechanism,Phenytoin Carbamazepine Rifampicin: patients treated potent inducers CYP3A4 (i.e. phenytoin carbamazepine_first rifampicin) clearance ondansetron significantly increased ondansetron_second blood concentrations decreased.
620,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",rifampicin,ondansetron,mechanism,Phenytoin Carbamazepine Rifampicin: patients treated potent inducers CYP3A4 (i.e. phenytoin carbamazepine rifampicin_first ) clearance ondansetron_second significantly increased ondansetron blood concentrations decreased.
621,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",rifampicin,ondansetron,mechanism,Phenytoin Carbamazepine Rifampicin: patients treated potent inducers CYP3A4 (i.e. phenytoin carbamazepine rifampicin_first ) clearance ondansetron significantly increased ondansetron_second blood concentrations decreased.
622,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",ondansetron,tramadol,effect,However basis available data dosage adjustment ondansetron recommended patients drugs.1 3 Tramadol: Although pharmacokinetic drug interaction ondansetron tramadol observed data 2 small studies indicate ondansetron_first may associated increase patient controlled administration tramadol_second .4 5 Chemotherapy: Tumor response chemotherapy P 388 mouse leukemia model affected ondansetron.
623,Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.,paclitaxel,HERCEPTIN,mechanism,Administration paclitaxel_first combination HERCEPTIN_second resulted two fold decrease HERCEPTIN clearance non human primate study 1.5 fold increase HERCEPTIN serum levels clinical studies.
624,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,macrolides,terfenadine,int,Concomitant administrations recommended: Terfenadine astemizole: Certain macrolides_first interact terfenadine_second astemizole leading increased serum concentrations latter.
625,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,macrolides,astemizole,int,Concomitant administrations recommended: Terfenadine astemizole: Certain macrolides_first interact terfenadine astemizole_second leading increased serum concentrations latter.
626,"Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ",roxithromycin,terfenadine,advise,Although reaction demonstrated roxithromycin concomitant administration roxithromycin_first terfenadine_second astemizole recommended.
627,"Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ",roxithromycin,astemizole,advise,Although reaction demonstrated roxithromycin concomitant administration roxithromycin_first terfenadine astemizole_second recommended.
628,"- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",pimozide,macrolide antibacterials,mechanism,Cisapride pimozide_first : drugs cisapride pimozide metabolised hepatic CYP3A isozymes associated QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) result increase serum level subsequent interaction significant inhibitors isozyme including macrolide antibacterials_second .
629,"- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",cisapride,macrolide antibacterials,mechanism,Cisapride pimozide: drugs cisapride_first pimozide metabolised hepatic CYP3A isozymes associated QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) result increase serum level subsequent interaction significant inhibitors isozyme including macrolide antibacterials_second .
630,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",Streptase,antiplatelet agents,effect,Use Anticoagulants Antiplatelet Agents Streptase_first Streptokinase alone combination antiplatelet agents_second anticoagulants may cause bleeding complications.
631,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",Streptase,anticoagulants,effect,Use Anticoagulants Antiplatelet Agents Streptase_first Streptokinase alone combination antiplatelet agents anticoagulants_second may cause bleeding complications.
632,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",Streptokinase,antiplatelet agents,effect,Use Anticoagulants Antiplatelet Agents Streptase Streptokinase_first alone combination antiplatelet agents_second anticoagulants may cause bleeding complications.
633,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",Streptokinase,anticoagulants,effect,Use Anticoagulants Antiplatelet Agents Streptase Streptokinase_first alone combination antiplatelet agents anticoagulants_second may cause bleeding complications.
634,"The addition of aspirin to Streptokinase causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see",aspirin,Streptokinase,effect,addition aspirin_first Streptokinase_second causes minimal increase risk minor bleeding (3.9% vs. 3.1%) appear increase incidence major bleeding (see
635,MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine. ,MAO inhibitors,pseudoephedrine,effect,MAO inhibitors_first beta adrenergic blockers increase effects pseudoephedrine_second .
636,MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine. ,beta adrenergic blockers,pseudoephedrine,effect,MAO inhibitors beta adrenergic blockers_first increase effects pseudoephedrine_second .
637,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",Sympathomimetics,methyldopa,effect,Sympathomimetics_first may reduce antihypertensive effects methyldopa_second mecamylamine reserpine veratrum alkaloids.
638,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",Sympathomimetics,mecamylamine,effect,Sympathomimetics_first may reduce antihypertensive effects methyldopa mecamylamine_second reserpine veratrum alkaloids.
639,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",Sympathomimetics,reserpine,effect,Sympathomimetics_first may reduce antihypertensive effects methyldopa mecamylamine reserpine_second veratrum alkaloids.
640,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",Sympathomimetics,veratrum alkaloids,effect,Sympathomimetics_first may reduce antihypertensive effects methyldopa mecamylamine reserpine veratrum alkaloids_second .
641,Distinct and statistically significant synergism was observed between methylglyoxal and piperacillin by disc diffusion tests when compared with their individual effects. ,methylglyoxal,piperacillin,effect,Distinct statistically significant synergism observed methylglyoxal_first piperacillin_second disc diffusion tests compared individual effects.
642,Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.,methylglyoxal,carbenicillin,effect,Synergism also noted methylglyoxal_first combined carbenicillin_second amikacin.
643,Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.,methylglyoxal,amikacin,effect,Synergism also noted methylglyoxal_first combined carbenicillin amikacin_second .
644,"Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. ",tetracyclines,anticoagulant,advise,tetracyclines_first shown depress plasma prothrombin activity patients anticoagulant_second therapy may require downward adjustment anticoagulant dosage.
645,"Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin. ",tetracycline class drugs,penicillin,advise,Since bacteriostatic drugs may interfere bactericidal action penicillin advisable avoid giving tetracycline class drugs_first conjunction penicillin_second .
646,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",tetracyclines,aluminum,mechanism,Absorption tetracyclines_first impaired antacids containing aluminum_second calcium magnesium iron containing preparations.
647,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",tetracyclines,calcium,mechanism,Absorption tetracyclines_first impaired antacids containing aluminum calcium_second magnesium iron containing preparations.
648,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",tetracyclines,magnesium,mechanism,Absorption tetracyclines_first impaired antacids containing aluminum calcium magnesium_second iron containing preparations.
649,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",tetracyclines,iron,mechanism,Absorption tetracyclines_first impaired antacids containing aluminum calcium magnesium iron_second containing preparations.
650,The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. ,tetracycline,methoxyflurane,effect,concurrent use tetracycline_first methoxyflurane_second reported result fatal renal toxicity.
651,Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.,tetracyclines,contraceptives,effect,Concurrent use tetracyclines_first oral contraceptives_second may render oral contraceptives less effective.
652,"The concomitant use of Sanctura with other anticholinergic agents that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects. ",Sanctura,anticholinergic agents,effect,concomitant use Sanctura_first anticholinergic agents_second produce dry mouth constipation anticholinergic pharmacological effects may increase frequency and/or severity effects.
653,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,digoxin,mechanism,Drugs Eliminated Active Tubular Secretion: Although studies assess drug drug interactions Sanctura conducted Sanctura_first potential pharmacokinetic interactions drugs eliminated active tubular secretion (e.g. digoxin_second procainamide pancuronium morphine vancomycin metformin tenofovir).
654,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,procainamide,mechanism,Drugs Eliminated Active Tubular Secretion: Although studies assess drug drug interactions Sanctura conducted Sanctura_first potential pharmacokinetic interactions drugs eliminated active tubular secretion (e.g. digoxin procainamide_second pancuronium morphine vancomycin metformin tenofovir).
655,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,pancuronium,mechanism,Drugs Eliminated Active Tubular Secretion: Although studies assess drug drug interactions Sanctura conducted Sanctura_first potential pharmacokinetic interactions drugs eliminated active tubular secretion (e.g. digoxin procainamide pancuronium_second morphine vancomycin metformin tenofovir).
656,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,morphine,mechanism,Drugs Eliminated Active Tubular Secretion: Although studies assess drug drug interactions Sanctura conducted Sanctura_first potential pharmacokinetic interactions drugs eliminated active tubular secretion (e.g. digoxin procainamide pancuronium morphine_second vancomycin metformin tenofovir).
657,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,vancomycin,mechanism,Drugs Eliminated Active Tubular Secretion: Although studies assess drug drug interactions Sanctura conducted Sanctura_first potential pharmacokinetic interactions drugs eliminated active tubular secretion (e.g. digoxin procainamide pancuronium morphine vancomycin_second metformin tenofovir).
658,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,metformin,mechanism,Drugs Eliminated Active Tubular Secretion: Although studies assess drug drug interactions Sanctura conducted Sanctura_first potential pharmacokinetic interactions drugs eliminated active tubular secretion (e.g. digoxin procainamide pancuronium morphine vancomycin metformin_second tenofovir).
659,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,tenofovir,mechanism,Drugs Eliminated Active Tubular Secretion: Although studies assess drug drug interactions Sanctura conducted Sanctura_first potential pharmacokinetic interactions drugs eliminated active tubular secretion (e.g. digoxin procainamide pancuronium morphine vancomycin metformin tenofovir_second ).
660,DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ,Nalidixic acid,melphalan,effect,DRUG INTERACTIONS known drug/drug interactions oral ALKERAN Vaccinations live organism vaccines recommended immunocompromised individuals Nalidixic acid_first together high dose intravenous melphalan_second caused deaths children due haemorrhagic enterocolitis.
661,Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous melphalan and who subsequently received cyclosporin to prevent graft-versus-host disease,melphalan,cyclosporin,effect,Impaired renal function described bone marrow transplant patients conditioned high dose intravenous melphalan_first subsequently received cyclosporin_second prevent graft versus host disease
662,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",midazolam,azole antimycotics,advise,Drug Interactions: Inhibitors CYP3A4 Isozymes: Caution advised midazolam_first administered concomitantly drugs known inhibit cytochrome P450 3A4 enzyme system (ie drugs drug classes azole antimycotics_second protease inhibitors calcium channel antagonists macrolide antibiotics).
663,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",midazolam,protease inhibitors,advise,Drug Interactions: Inhibitors CYP3A4 Isozymes: Caution advised midazolam_first administered concomitantly drugs known inhibit cytochrome P450 3A4 enzyme system (ie drugs drug classes azole antimycotics protease inhibitors_second calcium channel antagonists macrolide antibiotics).
664,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",midazolam,calcium channel antagonists,advise,Drug Interactions: Inhibitors CYP3A4 Isozymes: Caution advised midazolam_first administered concomitantly drugs known inhibit cytochrome P450 3A4 enzyme system (ie drugs drug classes azole antimycotics protease inhibitors calcium channel antagonists_second macrolide antibiotics).
665,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",midazolam,macrolide antibiotics,advise,Drug Interactions: Inhibitors CYP3A4 Isozymes: Caution advised midazolam_first administered concomitantly drugs known inhibit cytochrome P450 3A4 enzyme system (ie drugs drug classes azole antimycotics protease inhibitors calcium channel antagonists macrolide antibiotics_second ).
666,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",erythromycin,midazolam,mechanism,Drugs erythromycin_first diltiazem verapamil ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam_second .
667,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",diltiazem,midazolam,mechanism,Drugs erythromycin diltiazem_first verapamil ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam_second .
668,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",verapamil,midazolam,mechanism,Drugs erythromycin diltiazem verapamil_first ketoconazole fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam_second .
669,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",ketoconazole,midazolam,mechanism,Drugs erythromycin diltiazem verapamil ketoconazole_first fluconazole itraconazole shown significantly increase C max AUC orally administered midazolam_second .
670,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",fluconazole,midazolam,mechanism,Drugs erythromycin diltiazem verapamil ketoconazole fluconazole_first itraconazole shown significantly increase C max AUC orally administered midazolam_second .
671,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",itraconazole,midazolam,mechanism,Drugs erythromycin diltiazem verapamil ketoconazole fluconazole itraconazole_first shown significantly increase C max AUC orally administered midazolam_second .
672,"Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. ",ritonavir,midazolam,mechanism,Although studied potent cytochrome P450 3A4 inhibitors ritonavir_first nelfinavir may cause intense prolonged sedation respiratory depression due decrease plasma clearance midazolam_second .
673,"Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. ",nelfinavir,midazolam,mechanism,Although studied potent cytochrome P450 3A4 inhibitors ritonavir nelfinavir_first may cause intense prolonged sedation respiratory depression due decrease plasma clearance midazolam_second .
674,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",rifampin,midazolam,mechanism,Inducers CYP3A4 Isozymes: Cytochrome P450 inducers rifampin_first carbamazepine phenytoin induce metabolism caused markedly decreased C max AUC oral midazolam_second adult studies.
675,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",carbamazepine,midazolam,mechanism,Inducers CYP3A4 Isozymes: Cytochrome P450 inducers rifampin carbamazepine_first phenytoin induce metabolism caused markedly decreased C max AUC oral midazolam_second adult studies.
676,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",phenytoin,midazolam,mechanism,Inducers CYP3A4 Isozymes: Cytochrome P450 inducers rifampin carbamazepine phenytoin_first induce metabolism caused markedly decreased C max AUC oral midazolam_second adult studies.
677,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,narcotics,effect,sedative effect VERSED Syrup_first accentuated concomitantly administered medication depresses central nervous system particularly narcotics_second (eg morphine meperidine fentanyl) propofol ketamine nitrous oxide secobarbital droperidol.
678,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,morphine,effect,sedative effect VERSED Syrup_first accentuated concomitantly administered medication depresses central nervous system particularly narcotics (eg morphine_second meperidine fentanyl) propofol ketamine nitrous oxide secobarbital droperidol.
679,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,meperidine,effect,sedative effect VERSED Syrup_first accentuated concomitantly administered medication depresses central nervous system particularly narcotics (eg morphine meperidine_second fentanyl) propofol ketamine nitrous oxide secobarbital droperidol.
680,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,fentanyl,effect,sedative effect VERSED Syrup_first accentuated concomitantly administered medication depresses central nervous system particularly narcotics (eg morphine meperidine fentanyl_second ) propofol ketamine nitrous oxide secobarbital droperidol.
681,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,propofol,effect,sedative effect VERSED Syrup_first accentuated concomitantly administered medication depresses central nervous system particularly narcotics (eg morphine meperidine fentanyl) propofol_second ketamine nitrous oxide secobarbital droperidol.
682,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,ketamine,effect,sedative effect VERSED Syrup_first accentuated concomitantly administered medication depresses central nervous system particularly narcotics (eg morphine meperidine fentanyl) propofol ketamine_second nitrous oxide secobarbital droperidol.
683,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,nitrous oxide,effect,sedative effect VERSED Syrup_first accentuated concomitantly administered medication depresses central nervous system particularly narcotics (eg morphine meperidine fentanyl) propofol ketamine nitrous oxide_second secobarbital droperidol.
684,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,secobarbital,effect,sedative effect VERSED Syrup_first accentuated concomitantly administered medication depresses central nervous system particularly narcotics (eg morphine meperidine fentanyl) propofol ketamine nitrous oxide secobarbital_second droperidol.
685,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,droperidol,effect,sedative effect VERSED Syrup_first accentuated concomitantly administered medication depresses central nervous system particularly narcotics (eg morphine meperidine fentanyl) propofol ketamine nitrous oxide secobarbital droperidol_second .
686,"Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.",Leukine,lithium,effect,Drugs may potentiate myeloproliferative effects Leukine_first lithium_second corticosteroids used caution.
687,"Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.",Leukine,corticosteroids,effect,Drugs may potentiate myeloproliferative effects Leukine_first lithium corticosteroids_second used caution.
688,"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors. ",TRENTAL,anticoagulants,effect,Although causal relationship established reports bleeding and/or prolonged prothrombin time patients treated TRENTAL_first without anticoagulants_second platelet aggregation inhibitors.
689,"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors. ",TRENTAL,platelet aggregation inhibitors,effect,Although causal relationship established reports bleeding and/or prolonged prothrombin time patients treated TRENTAL_first without anticoagulants platelet aggregation inhibitors_second .
690,Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. ,TRENTAL,theophylline,mechanism,Concomitant administration TRENTAL_first theophylline_second containing drugs leads increased theophylline levels theophylline toxicity individuals.
691,ACE inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors. ,NSAIDs,angiotensin-converting enzyme (ACE) inhibitors,effect,ACE inhibitors Reports suggest NSAIDs_first may diminish antihypertensive effect angiotensin-converting enzyme (ACE) inhibitors_second .
692,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. ,NSAIDs,ACE inhibitors,advise,interaction given consideration patients taking NSAIDs_first concomitantly ACE inhibitors_second .
693,Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam. ,aspirin,meloxicam,mechanism,Aspirin: Concomitant administration aspirin_first (1000 mg TID) healthy volunteers tended increase AUC (10%) Cmax (24%) meloxicam_second .
694,"however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. ",NSAIDs,aspirin,advise,however NSAIDs_first concomitant administration meloxicam aspirin_second generally recommended potential increased adverse effects.
695,"however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. ",meloxicam,aspirin,advise,however NSAIDs concomitant administration meloxicam_first aspirin_second generally recommended potential increased adverse effects.
696,"Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone. ",aspirin,MOBIC,effect,Concomitant administration low dose aspirin_first MOBIC_second may result increased rate GI ulceration complications compared use MOBIC alone.
697,Cholestyramine: Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%. ,cholestyramine,meloxicam,mechanism,Cholestyramine: Pretreatment four days cholestyramine_first significantly increased clearance meloxicam_second 50%.
698,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. ",NSAIDs,furosemide,effect,Furosemide: Clinical studies well post marketing observations shown NSAIDs_first reduce natriuretic effect furosemide_second thiazide diuretics patients.
699,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. ",NSAIDs,thiazide diuretics,effect,Furosemide: Clinical studies well post marketing observations shown NSAIDs_first reduce natriuretic effect furosemide thiazide diuretics_second patients.
700,"Nevertheless, during concomitant therapy with furosemide and MOBIC, patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy. ",furosemide,MOBIC,advise,Nevertheless concomitant therapy furosemide_first MOBIC_second patients observed closely signs declining renal function well assure diuretic efficacy.
701,"Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. ",NSAIDs,lithium,mechanism,Lithium: clinical trials NSAIDs_first produced elevation plasma lithium_second levels reduction renal lithium clearance.
702,"In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. ",lithium,meloxicam,mechanism,study conducted healthy subjects mean pre dose lithium concentration AUC increased 21% subjects receiving lithium_first doses ranging 804 1072 mg BID meloxicam_second 15 mg QD compared subjects receiving lithium alone.
703,Patients on lithium treatment should be closely monitored when MOBIC is introduced or withdrawn. ,lithium,MOBIC,advise,Patients lithium_first treatment closely monitored MOBIC_second introduced withdrawn.
704,"Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBIC therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding. ",MOBIC,warfarin,advise,Warfarin: Anticoagulant activity monitored particularly first days initiating changing MOBIC_first therapy patients receiving warfarin_second similar agents since patients increased risk bleeding.
705,Caution should be used when administering MOBIC with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,MOBIC,warfarin,advise,Caution used administering MOBIC_first warfarin_second since patients warfarin may experience changes INR increased risk bleeding complications new medication introduced.
706,"When administered concomitantly with ProAmatine   , cardiac glycosides may enhance or precipitate bradycardia, A.V. ",ProAmatine,cardiac glycosides,effect,administered concomitantly ProAmatine_first cardiac glycosides_second may enhance precipitate bradycardia A.V.
707,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",phenylephrine,ProAmatine,effect,use drugs stimulate alpha adrenergic receptors (e.g. phenylephrine_first pseudoephedrine ephedrine phenylpropanolamine dihydroergotamine) may enhance potentiate pressor effects ProAmatine_second . Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction.
708,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",pseudoephedrine,ProAmatine,effect,use drugs stimulate alpha adrenergic receptors (e.g. phenylephrine pseudoephedrine_first ephedrine phenylpropanolamine dihydroergotamine) may enhance potentiate pressor effects ProAmatine_second . Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction.
709,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",ephedrine,ProAmatine,effect,use drugs stimulate alpha adrenergic receptors (e.g. phenylephrine pseudoephedrine ephedrine_first phenylpropanolamine dihydroergotamine) may enhance potentiate pressor effects ProAmatine_second . Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction.
710,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",phenylpropanolamine,ProAmatine,effect,use drugs stimulate alpha adrenergic receptors (e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine_first dihydroergotamine) may enhance potentiate pressor effects ProAmatine_second . Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction.
711,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",dihydroergotamine,ProAmatine,effect,use drugs stimulate alpha adrenergic receptors (e.g. phenylephrine pseudoephedrine ephedrine phenylpropanolamine dihydroergotamine_first ) may enhance potentiate pressor effects ProAmatine_second . Therefore caution used ProAmatine administered concomitantly agents cause vasoconstriction.
712,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",Alpha-adrenergic blocking agents,ProAmatine,effect,ProAmatine. Alpha-adrenergic blocking agents_first prazosin terazosin doxazosin antagonize effects ProAmatine_second . Potential Drug Interactions: appears possible although supporting experimental evidence high renal clearance desglymidodrine (a base) due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene flecainide quinidine.
713,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",prazosin,ProAmatine,effect,ProAmatine. Alpha adrenergic blocking agents prazosin_first terazosin doxazosin antagonize effects ProAmatine_second . Potential Drug Interactions: appears possible although supporting experimental evidence high renal clearance desglymidodrine (a base) due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene flecainide quinidine.
714,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",terazosin,ProAmatine,effect,ProAmatine. Alpha adrenergic blocking agents prazosin terazosin_first doxazosin antagonize effects ProAmatine_second . Potential Drug Interactions: appears possible although supporting experimental evidence high renal clearance desglymidodrine (a base) due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene flecainide quinidine.
715,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",doxazosin,ProAmatine,effect,ProAmatine. Alpha adrenergic blocking agents prazosin terazosin doxazosin_first antagonize effects ProAmatine_second . Potential Drug Interactions: appears possible although supporting experimental evidence high renal clearance desglymidodrine (a base) due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene flecainide quinidine.
716,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,metformin,mechanism,ProAmatine. Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine. Potential Drug Interactions: appears possible although supporting experimental evidence high renal clearance desglymidodrine_first (a base) due active tubular secretion base secreting system also responsible secretion drugs metformin_second cimetidine ranitidine procainamide triamterene flecainide quinidine.
717,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,cimetidine,mechanism,ProAmatine. Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine. Potential Drug Interactions: appears possible although supporting experimental evidence high renal clearance desglymidodrine_first (a base) due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine_second ranitidine procainamide triamterene flecainide quinidine.
718,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,ranitidine,mechanism,ProAmatine. Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine. Potential Drug Interactions: appears possible although supporting experimental evidence high renal clearance desglymidodrine_first (a base) due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine_second procainamide triamterene flecainide quinidine.
719,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,procainamide,mechanism,ProAmatine. Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine. Potential Drug Interactions: appears possible although supporting experimental evidence high renal clearance desglymidodrine_first (a base) due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide_second triamterene flecainide quinidine.
720,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,triamterene,mechanism,ProAmatine. Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine. Potential Drug Interactions: appears possible although supporting experimental evidence high renal clearance desglymidodrine_first (a base) due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene_second flecainide quinidine.
721,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,flecainide,mechanism,ProAmatine. Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine. Potential Drug Interactions: appears possible although supporting experimental evidence high renal clearance desglymidodrine_first (a base) due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene flecainide_second quinidine.
722,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,quinidine,mechanism,ProAmatine. Alpha adrenergic blocking agents prazosin terazosin doxazosin antagonize effects ProAmatine. Potential Drug Interactions: appears possible although supporting experimental evidence high renal clearance desglymidodrine_first (a base) due active tubular secretion base secreting system also responsible secretion drugs metformin cimetidine ranitidine procainamide triamterene flecainide quinidine_second .
723,Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.,cimetidine,mebendazole,mechanism,Preliminary evidence suggests cimetidine_first inhibits mebendazole_second metabolism may result increase plasma concentrations mebendazole.
724,Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin,Alcohol,riboflavin,mechanism,Interactions Vitamin B2 (Riboflavin): Alcohol_first impairs intestinal absorption riboflavin_second
725,Probenecid - concurrent use decreases gastrointestinal absorption of riboflavin; ,Probenecid,riboflavin,mechanism,Probenecid_first concurrent use decreases gastrointestinal absorption riboflavin_second ;
726,requirements for riboflavin may be increased in patients receiving probenecid.,riboflavin,probenecid,effect,requirements riboflavin_first may increased patients receiving probenecid_second .
727,"Anticholinergics or other medications with anticholinergic activity when used concurrently with opioid analgesics may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. ",Anticholinergics,opioid analgesics,effect,Anticholinergics_first medications anticholinergic activity used concurrently opioid analgesics_second may result increased risk urinary retention and/or severe constipation may lead paralytic ileus.
728,It has been reported that the incidence of bradycardia was increased when oxymorphone was combined with propofol for induction of anesthesia. ,oxymorphone,propofol,effect,reported incidence bradycardia increased oxymorphone_first combined propofol_second induction anesthesia.
729,"In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of cimetidine with opioid analgesics; ",cimetidine,opioid analgesics,effect,addition CNS toxicity reported (confusion disorientation respiratory depression apnea seizures) following coadministration cimetidine_first opioid analgesics_second ;
730,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",Celontin,antiepileptic drugs,advise,Since Celontin_first (methsuximide) may interact concurrently administered antiepileptic drugs_second periodic serum level determinations drugs may necessary (eg methsuximide may increase plasma concentrations phenytoin phenobarbital).
731,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",methsuximide,antiepileptic drugs,advise,Since Celontin (methsuximide_first ) may interact concurrently administered antiepileptic drugs_second periodic serum level determinations drugs may necessary (eg methsuximide may increase plasma concentrations phenytoin phenobarbital).
732,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",methsuximide,phenytoin,mechanism,Since Celontin (methsuximide) may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary (eg methsuximide_first may increase plasma concentrations phenytoin_second phenobarbital).
733,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",methsuximide,phenobarbital,mechanism,Since Celontin (methsuximide) may interact concurrently administered antiepileptic drugs periodic serum level determinations drugs may necessary (eg methsuximide_first may increase plasma concentrations phenytoin phenobarbital_second ).
734,"When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. ",atropine,pralidoxime,effect,atropine_first pralidoxime_second used together signs atropinization (flushing mydriasis tachycardia dryness mouth nose) may occur earlier might expected atropine used alone.
735,"2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions; ",barbiturates,anticholinesterases,effect,2 4 following precautions kept mind treatment anticholinesterase poisoning although bear directly use pralidoxime: since barbiturates_first potentiated anticholinesterases_second used cautiously treatment convulsions;
736,Anticoagulants Anabolic steroids may increase sensitivity to oral anticoagulants. ,Anabolic steroids,anticoagulants,effect,Anticoagulants Anabolic steroids_first may increase sensitivity oral anticoagulants_second .
737,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",oxandrolone,warfarin,mechanism,Warfarin: multidose study oxandrolone_first given 5 10 mg BID 15 healthy subjects concurrently treated warfarin_second resulted mean increase warfarin half life 26 48 hours AUC 4.55 12.08 ng*hr/mL: similar increases R warfarin half life AUC also detected.
738,"When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved. ",oxandrolone,warfarin,advise,oxandrolone_first therapy initiated patient already receiving treatment warfarin_second INR prothrombin time (PT) monitored closely dose warfarin adjusted necessary stable target INR PT achieved.
739,"Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the warfarin dosage if indicated are recommended when the oxandrolone dose is changed or discontinued. ",warfarin,oxandrolone,advise,Furthermore patients receiving drugs careful monitoring INR PT adjustment warfarin_first dosage indicated recommended oxandrolone_second dose changed discontinued.
740,Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents. ,Oxandrolone,hypoglycemic agents,mechanism,Oral hypoglycemic agents Oxandrolone_first may inhibit metabolism oral hypoglycemic agents_second .
741,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Moxifloxacin,sucralfate,mechanism,Moxifloxacin_first Lomefloxacin reacts faster sucralfate_second gelusil acidic media whereas erythromycin basic media multi minerals neutral media.
742,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Moxifloxacin,gelusil,mechanism,Moxifloxacin_first Lomefloxacin reacts faster sucralfate gelusil_second acidic media whereas erythromycin basic media multi minerals neutral media.
743,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Moxifloxacin,erythromycin,mechanism,Moxifloxacin_first Lomefloxacin reacts faster sucralfate gelusil acidic media whereas erythromycin_second basic media multi minerals neutral media.
744,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Moxifloxacin,multi-minerals,mechanism,Moxifloxacin_first Lomefloxacin reacts faster sucralfate gelusil acidic media whereas erythromycin basic media multi-minerals_second neutral media.
745,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Lomefloxacin,sucralfate,mechanism,Moxifloxacin Lomefloxacin_first reacts faster sucralfate_second gelusil acidic media whereas erythromycin basic media multi minerals neutral media.
746,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Lomefloxacin,gelusil,mechanism,Moxifloxacin Lomefloxacin_first reacts faster sucralfate gelusil_second acidic media whereas erythromycin basic media multi minerals neutral media.
747,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Lomefloxacin,erythromycin,mechanism,Moxifloxacin Lomefloxacin_first reacts faster sucralfate gelusil acidic media whereas erythromycin_second basic media multi minerals neutral media.
748,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Lomefloxacin,multi-minerals,mechanism,Moxifloxacin Lomefloxacin_first reacts faster sucralfate gelusil acidic media whereas erythromycin basic media multi-minerals_second neutral media.
749,Methysergide may reverse the analgesic activity of narcotic analgesics. ,Methysergide,narcotic analgesics,effect,Methysergide_first may reverse analgesic activity narcotic analgesics_second .
750,Zidovudine competitively inhibits the intracellular phosphorylation of stavudine. ,Zidovudine,stavudine,effect,Zidovudine_first competitively inhibits intracellular phosphorylation stavudine_second .
751,"Therefore, use of zidovudine in combination with ZERIT should be avoided. ",zidovudine,ZERIT,advise,Therefore use zidovudine_first combination ZERIT_second avoided.
752,In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. ,stavudine,doxorubicin,effect,vitro data indicate phosphorylation stavudine_first also inhibited relevant concentrations doxorubicin_second ribavirin.
753,In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. ,stavudine,ribavirin,effect,vitro data indicate phosphorylation stavudine_first also inhibited relevant concentrations doxorubicin ribavirin_second .
754,"When administered concurrently, testolactone may increase the effects of oral anticoagulants; ",testolactone,anticoagulants,effect,administered concurrently testolactone_first may increase effects oral anticoagulants_second ;
755,Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. ,Paroxetine,endoxifen,mechanism,Paroxetine_first fluoxetine reduce plasma concentration endoxifen_second 50%.
756,Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. ,fluoxetine,endoxifen,mechanism,Paroxetine fluoxetine_first reduce plasma concentration endoxifen_second 50%.
757,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ",tamoxifen,SSRI antidepressants,advise,better avoid prescribing isoenzyme CYP 2D6 inhibitors women treated tamoxifen_first breast cancer especially SSRI antidepressants_second paroxetine fluoxetine.
758,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ",tamoxifen,paroxetine,advise,better avoid prescribing isoenzyme CYP 2D6 inhibitors women treated tamoxifen_first breast cancer especially SSRI antidepressants paroxetine_second fluoxetine.
759,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ",tamoxifen,fluoxetine,advise,better avoid prescribing isoenzyme CYP 2D6 inhibitors women treated tamoxifen_first breast cancer especially SSRI antidepressants paroxetine fluoxetine_second .
760,"If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.",antidepressant,tamoxifen,advise,certain cases antidepressant_first considered necessary may advisable replace tamoxifen_second anastrozole.
761,"But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). ",amlodipine,valsartan,effect,use fixed combination amlodipine_first /valsartan_second compared traditional therapy associated lower clinical self measured BP quicker achievement target BP (5.8+/ 2.3 9.2+/ 1.8 days respectively 0.05) lesser number antihypertensive drugs (2.5+/ 0.6 3.0+/ 0.9 days respectively) lower rate concealed inefficacy treatment (12 31% respectively 0.05).
762,"We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.",amlodipine,valsartan,effect,demonstrated appropriateness inhospital administration fixed amlodipine_first /valsartan_second combination approach allowing achieve target BP shorter time use fewer antihypertensive drugs diminishing concealed inefficacy treatment.
763,Cholestyramine: Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55%. ,cholestyramine,ezetimibe,mechanism,Cholestyramine: Concomitant cholestyramine_first administration decreased mean AUC total ezetimibe_second approximately 55%.
764,The incremental LDL-C reduction due to adding ezetimibe to cholestyramine may be reduced by this interaction. ,ezetimibe,cholestyramine,effect,incremental LDL C reduction due adding ezetimibe_first cholestyramine_second may reduced interaction.
765,Co-administration of ZETIA with fibrates is not recommended until use in patients is studied. ,ZETIA,fibrates,advise,Co administration ZETIA_first fibrates_second recommended use patients studied.
766,"Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold. ",fenofibrate,ezetimibe,mechanism,Fenofibrate: pharmacokinetic study concomitant fenofibrate_first administration increased total ezetimibe_second concentrations approximately 1.5 fold.
767,"Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine. ",ezetimibe,cyclosporine,mechanism,Cyclosporine: total ezetimibe_first level increased 12 fold one renal transplant patient receiving multiple medications including cyclosporine_second .
768,Patients who take both ezetimibe and cyclosporine should be carefully monitored. ,ezetimibe,cyclosporine,advise,Patients take ezetimibe_first cyclosporine_second carefully monitored.
769,Imexon and dacarbazine show additive effects in vitro but not in vivo in human A375 melanoma cells.,Imexon,dacarbazine,effect,Imexon_first dacarbazine_second show additive effects vitro vivo human A375 melanoma cells.
770,"Acute administration of hemantane or doxycycline failed to influence locomotion in mice, while their combination normalized motor activity. ",hemantane,doxycycline,effect,Acute administration hemantane_first doxycycline_second failed influence locomotion mice combination normalized motor activity.
771,"However, ketoconazole, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing.",ketoconazole,mometasone furoate,mechanism,However ketoconazole_first potent inhibitor cytochrome P450 3A4 may increase plasma levels mometasone furoate_second concomitant dosing.
772,"ABT decreased the toxicity of precocene I, increased exposure to parent compound, and decreased metabolite levels in a dose-dependent manner. ",ABT,precocene I,effect,ABT_first decreased toxicity precocene I_second increased exposure parent compound decreased metabolite levels dose dependent manner.
773,"Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. ",quinidine,precocene I,effect,Furafylline sulfaphenazole effect quinidine_first appeared augment precocene I_second toxicity.
774,"SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.",SKELAXIN,alcohol,effect,SKELAXIN_first may enhance effects alcohol_second barbiturates CNS depressants.
775,"SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.",SKELAXIN,barbiturates,effect,SKELAXIN_first may enhance effects alcohol barbiturates_second CNS depressants.
776,"SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.",SKELAXIN,CNS depressants,effect,SKELAXIN_first may enhance effects alcohol barbiturates CNS depressants_second .
